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2. Introduction to Thymic epithelial tumors 
2.1 Epidemiology 
In the European Union non-communicable diseases that affect less than five in 10,000 
people are considered rare (European Commission). In a population-based study using 
two nationwide databases in the Netherlands the incidence of thymic epithelial tumors 
(TETs) was reported to be 3.2/1,000,000 (de Jong, Blaauwgeers et al. 2008). The overall 
annual incidence in the United States was reported as 0.15 per 100,000 inhabitants 
(Engels and Pfeiffer 2003). TETs are thus an orphan disease.  
Two distinct forms of TETs can be distinguished: thymomas and thymic carcinomas 
(TC). In the Netherlands (1994-2003) thymoma incidence was 2.2/1,000,000 and TC in-
cidence 0.3/1,000,000 with equal incidence rates for men and women (de Jong, 
Blaauwgeers et al. 2008). In the Netherlands the median age at diagnosis of TETs was 59 
years (de Jong, Blaauwgeers et al. 2008). 
Among the rarest forms of TETs are  thymic neuroendocrine tumors (TNETs). They ac-
counted for 0.4% of carcinoid tumors in the Surveillance, Epidemiology, and End Results 
(SEER) database of the United States National Cancer Institute (Yao, Hassan et al. 2008, 
Gaur, Leary et al. 2010) and constitute about 4-7% of all anterior mediastinal tumors 
(Gaur, Leary et al. 2010). 
2.2 Etiology and heredity 
To date no risk factors for the development of TETs have been discovered. Regarding the 
existence of genetic variants a higher risk of thymomas in diverse Asian and Pacific Is-
landers was reported. So far no evidence for the contribution of alcohol, tobacco, occu-
pational or environmental hazards, dietary factors or  ionizing radiation could be detected. 
The incidence of TETs seems not to be higher in immunosuppressed HIV patients or 
organ transplant recipients (Engels and Pfeiffer 2003). Epstein Barr virus (EBV) was de-
tected in TCs of lymphoepithelial histology (Mann, Wu et al. 1992, Engels and Pfeiffer 
2003).  
The familial occurrence of thymomas is a very rare event. In one family thymomas oc-




such as Grave`s disease, pernicious anemia, Sjögren`s diease and autoimmune pancyto-
penia). Of the 27 tested family members 11 had a constitutional translocation 
t(14;20)(q24;p12) which was present in all the thymoma patients of this family. The DNA 
strand break 14q24 was in a tumor suppressor gene (RAD5I family) known to be involved 
in tumors such as uterine leiomyoma or pulmonary chondroid hamartoma). The DNA 
strand break 20p12 was in close proximity (100kb) to BMP2, a TGFβ-family member 
involved in the differentiation of thymocytes (Nicodeme, Geffroy et al. 2005). 
2.3 Histology 
2.3.1 Thymoma and TC 
In 1999 the WHO defined histopathological criteria for thymomas, namely types A, AB, 
B1, B2, B3 and for the different TC subtypes collectively as type C (J.). In the year 2002 
the new WHO Histologic Classification of TETs was published (Chen, Marx et al. 2002). 
In the fourth edition of the WHO Classification of Thymic Tumors (TETs, germ cell tu-
mors, lymphomas, dendritic cell and myeloid neoplasms, and soft tissue tumors of the 
thymus and mediastinum) a comprehensive overview of newly defined tumor entities and 
their variants as well as refined criteria for the diagnosis of thymomas and thymic squa-
mous cell carcinoma (see Table 2; and reference (Marx, Chan et al. 2015)). 
 
Table 1: WHO classification of TETs. Adapted from Table 1: Epithelial Tumors: The 2015 World Health 
Organization Classification of Tumors of the Thymus: Continuity and Changes (Marx, Chan et al. 2015). 
Behavior is coded /0 for benign tumors; /1 for unspecified, borderline, or uncertain behavior; /2 for carci-
noma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumors. NUT, nuclear protein in 
testis. aThese new codes were approved by the IARC/WHO Committee for ICD-0. 
Thymoma ICD-O 
 Type A thymoma, including atypical variant 8581/3a 
 Type AB thymoma 8582/3a 
 Type B1 thymoma 8583/3a 
 Type B2 thymoma 8584/3a 
 Type B3 thymoma 8585/3a 
 Micronodular thymoma with lymphoid stroma 8580/1a 
 Metaplastic thymoma Other rare thymomas 8580/3 
 Microscopic thymoma 8580/0 
 Sclerosing thymoma 8580/3 
 Lipofibroadenoma 9010/0a 
Thymic carcinoma  
 Squamous cell carcinoma 8070/3 




 Mucoepidermoid carcinoma 8430/3 
 Lymphoepithelioma-like carcinoma 8082/3 
 Clear cell carcinoma 8310/3 
 Sarcomatoid carcinoma 8033/3 
 Adenocarcinomas  
 Papillary adenocarcinoma 8260/3 
Thymic carcinoma with adenoid cystic carcinoma-like features 8200/3a 
 Mucinous adenocarcinoma 8480/3 
 Adenocarcinoma, NOS 8140/3 
 NUT carcinoma 8023/3a 
 Undifferentiated carcinoma 8020/3 
 Other rare thymic carcinomas  
 Adenosquamous carcinoma 8560/3 
 Hepatoid carcinoma 8576/3 
Thymic carcinoma, NOS 8586/3 
 Thymic neuroendocrine tumors  
 Carcinoid tumors  
 Typical carcinoid 8240/3 
 Atypical carcinoid 8249/3 
 Large-cell neuroendocrine carcinoma 8013/3 
 Combined large-cell neuroendocrine carcinoma 8013/3 
 Small-cell carcinoma (SCC) 8041/3 
 Combined SCC 8045/3 
Combined thymic carcinomas   
 
Table 2: WHO classification of thymic tumors: refined diagnostic criteria. From: The 2015 WHO Classifi-
cation of Tumors of the Thymus: Continuity and Changes (Marx, Chan et al. 2015). aPaucity versus abun-
dance: any area of crowded immature T cells or moderate numbers of immature T cells in >10% of the investigated 
tumor are indicative of “abundance”; 
Thymoma subtype Obligatory criteria Optional criteria 
Type A Occurrence of bland, spindle shaped epithelial 
cells (at least focally); paucitya or absence of im-
mature (TdT+) T cells throughout the tumor 
Polygonal epithelial cells CD20+ 
epithelial cells 
Atypical type A variant Criteria of type A thymoma; in addition: comedo-
type tumor necrosis; increased mitotic count 
(>4/2mm2); nuclear crowding 
Polygonal epithelial cells CD20+ 
epithelial cells 
Type AB Occurrence of bland, spindle shaped epithelial 
cells (at least focally); abundancea of immature 
(TdT+) T cells focally or throughout tumor 
Polygonal epithelial cells 
CD20+epithelial cells 
Type B1 Thymus-like architecture and cytology: abun-
dance of immature T cells, areas of medullary dif-
ferentiation (medullary islands); paucity of polyg-
onal or dendritic epithelia cells without clustering 
(i.e.<3 contiguous epithelial cells) 
Hassall’s corpuscles; perivas-
cular spaces 
Type B2 Increased numbers of single or clustered polygo-
nal or dendritic epithelial cells intermingled with 
abundant immature T cells 
Medullary islands; Hassall’s cor-
puscles; perivascular spaces 
Type B3 Sheets of polygonal slightly to moderately atypical 
epithelial cells; absent or rare intercellular bridges; 




momas (MNT) with 
lymphoid stroma; 
 
Nodules of bland spindle or oval epithelial cells 
surrounded by an epithelial cell-free lymphoid 
stroma 
Lymphoid follicles; monoclonal 




Metaplastic thymoma Biphasic tumor composed of solid areas of epithe-
lial cells in a background of bland-looking spindle 
cells; absence of immature T cells 
Pleomorphism of epithelial cells; 
actin, keratin, or EMA-positive 
spindle cells 
Rare other: Microscopic thymoma; sclerosing thymoma, lipofibroadenoma 
 
 
Outcome related to WHO histology 
In a study on 200 Chinese patients undergoing surgery for TETs (only 55 patients re-
ceived adjuvnat radiotherapy and 8 patients adjuvant chemotherapy) OS was reported as 
follows: none of the Type A and AB thymomas patients died of tumor; there was one 
patient with type B1 thymoma who died at 22 months; type B2, B3, and TC (formerly 
type C thymomas) patients had a significantly worse prognosis: 5-year OS 75.0%, 70.0%, 
and 48.0%, respectively (see Figure 1). Masaoka-Koga stage was a statistically significant 
predictor of survival. There was a statistically significant association between WHO his-
tologic subtype and stage. WHO histology was an independent predictive factor of OS in 
stage I and II TETs: type B2, B3, and TC had a worse prognosis than type A, AB, and B1 
thymomas (p<0.003) (Chen, Marx et al. 2002). 
 
Figure 1: OS by Stage and WHO histology. Patients with higher stage had a significantly (p<0.001) in-
creased risk of death from tumor. Type B2-3 and C thymomas (TCs) had a significantly (p<0.01) increased 
risk of death from tumor. From (Chen, Marx et al. 2002). 
 
Our group has recently proposed a new subtype of TC: primary thymic adenocarcinoma 
of enteric type (Moser, Schiefer et al. 2015). The inclusion of this new TC subtype may 
help prevent misdiagnosis of metastatic disease from an extrathymic primary cancer, par-





Figure 2: Primary thymic adenocarcinoma of enteric type. Hematoxylin and eosin staining (A). Immuno-
histochemistry for CK20 (B), CDX2 (C), and CEA (D). From (Moser, Schiefer et al. 2015). 
2.3.2 TNETs 
The current nomenclature of TNETs distinguishes: thymic typical (<2 mitoses/2mm2; no 
necrosis) and atypical (<2 mitoses/2mm2; with necrosis; or 2–10 mitoses/2mm2; + or − 
necrosis) carcinoids, large cell neuroendocrine carcinoma (LCNEC; >10 mitoses/2mm2; 
no small cell features) and small cell carcinoma; and the  combination of LCNEC or small 
cell carcinoma with thymoma of TC (Marx, Chan et al. 2015). Pathognomonic for TNETs 
is their high biologic aggressiveness and poor prognosis due to high recurrences rates and 
tumor related deaths (Strobel, Zettl et al. 2014, Filosso, Yao et al. 2015). OS of patients 
with TNETs in the SEER database at 1-, 3- and 5 years was 89%, 66% and 53% with 
poorer survival of patients in advanced stages (Gaur, Leary et al. 2010). 5 year OS for 
localized disease (tumor confined to organ) was 80%, regional disease (local invasion or 
metastasis to regional lymph nodes) 48% and distant disease 31% (Gaur, Leary et al. 
2010). OS was reported to be significantly better in patients undergoing macroscopic 
complete resection (Ose, Maeda et al. 2018). TNETs can be associated with parane-
oplastic syndromes, e.g. Cushing`s syndrome or multiple endocrine neoplasia syndrome 







2.3.3 Thymic hyperplasia 
Thymic hyperplasia (TH) is caused by non-malignant thymic changes with an increase in 
constituent cells (Castleman 1955). Pathology distinguishes two inherently different types 
of TH.  True thymic hyperplasia (TTH) is diagnosed if the thymus is of regular micro-
scopic histologic architecture but is marked by increased weight and size. Follicular (or 
lymphoid) TH (FTH) is characterized by the presence of lymphoid follicles with germinal 
centers in the thymic medulla (Rosai and Levine 1976). The diagnosis benign enlarge-
ment of the thymus :TTH and FTH can solely be made from the pathological specimen. 
To date there are no established risk factors (Engels 2010) nor biomarkers that can dis-
tinguish TH from malignant TETs. 
2.4 Paraneoplastic syndromes: 
There is a strong association between thymomas and autoimmune diseases: systemic lu-
pus erythematosus, autoimmune cytopenias (pure red cell aplasia (PRCA), aplastic ane-
mia (AA), autoimmune hemolytic anemia (AIHA), immune thrombocytopenia, autoim-
mune neutropenia, thrombotic thrombocytopenic purpura, agranulocytosis, polymyositis, 
Good`s syndrome, hypogammaglobulinemia, autoimmune thyroid diseases, autoimmune 
hepatitis, cutaneous autoimmune diseases, paraneoplastic pemphigus or Lichen planus 
(Bernard, Frih et al. 2016). Many of the observed paraneoplastic disease are neurological: 
Myasthenia gravis, Lambert Eaton syndrome, Myositis, Isaac`s syndrome, encephalitis, 
Morvan`s syndrome, Autoimmune Autonomic Neuropathy, Paraneoplastic cerebellar de-
generation, Stiff person syndrome (Evoli and Lancaster 2014). The most frequent para-
neoplastic autoimmune neurological disorder is MG. TETs are diagnosed in up to 15% 
of patients with MG. Conversely, about 30% of patients with TETs experience symptoms 
of MG at the time of diagnosis (Marx, Willcox et al. 2010). 
2.4.1 Myasthenia gravis 
Myasthenia gravis (MG) is a neurological disorder with a prevalence of 10/100,000 peo-
ple (Phillips 2003). MG is a B-cell mediated autoimmune disorder (Gilhus and 
Verschuuren 2015) characterized by autoantibodies against the nicotinic acetylcholine 
receptor and less common against other proteins of the neuromuscular junction. The au-




neuromuscular junction and leads to the patients’ pathognomonic fluctuating muscle 
weakness (Vincent 2002). MG is more prevalent in patients with B-type thymomas than 
types A or AB and is not observed in patients with TCs (Chen, Marx et al. 2002, 
Radovich, Pickering et al. 2018) Table 3.  
 
Table 3: Frequency of the different histological TET subtypes in relation to MG and stage Adopted from 
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 
(Girard, Ruffini et al. 2015). The statistics were derived from four publications (Kojima, Ito et al. 2006, 
Ruffini, Detterbeck et al. 2014, Omasa, Date et al. 2015, Weis, Yao et al. 2015). 
 Relative frequency  Myasthenia gravis  Masaoka stage  
I  II  III  IVA  IVB  
Type A  12 (3–26)  15 (0–35)  60  31  8  <1  <1  
Type AB  28 (15–43)  20 (5–42)  67  26  6  1 1  
Type B1  18 (6–53)  40 (5–69)  50  37  9  3  1  
Type B2  26 (8–41)  50 (23–73)  32  29  28  8  3  
Type B3  16 (3–35)  50 (25–65)  19 36 27 1  3 




Intrathymic pathogenesis of MG 
MG is a well described autoimmune disease with well identified autoimmune targets and 
autoimmune effector mechanisms  (Levinson 2013). Evidence for the role of thymus in 
pathogenesis of MG was collected: pathological evidence (germinal center hyperplasia 
and thymomas), clinical evidence (treatment benefits of surgical thymectomy), immuno-
logical evidence (thymic B cells and CD4+ T cells reactive to  nicotinic acetylcholine 
receptors (AChRα), decreased function and number of thymic regulatory T cells, in-
creased chemokine expression (CXCL13 and CCL21) of hyperplastic thymi of MG pa-
tients) and structural evidence (nicotinic AChR subunits expressed on myoid cells and 
thymic epithelial cells). Despite the increase in knowledge on MG the events leading to 
a loss of self tolerance to AChRs remain elusive (Levinson 2013). 
Recently, the first randomized controlled trial of thymectomy in non-thymomatous MG 
confirmed the clinical improvement of patients undergoing thymectomy (Wolfe, 
Kaminski et al. 2016). 
Thymoma-associated MG (TAMG) 
Multi-omic analysis of TAMG as part of the “The Cancer Genome Atlas” project ob-




Pickering et al. 2018). Interestingly, the presence of MG was not associated with muta-
tions in single genes or methylation patterns in TETs compared to MG negative TETs 
(e.g. GTF2I). Tumors of TAMG patients revealed an overexpression of genes with lim-
ited (NEFM) or extensive (RYR3) sequence similarity of autoimmune targets. Thus thy-
momas and MG were linked by the expression of known autoimmune targets (muscle 
autoantigens) and increased aneuploidy (Radovich, Pickering et al. 2018). 
 
2.5 Molecular biology 
Molecular profiling utilizing next generation gene panel sequencing combined with FISH 
and immunohistochemistry can be utilized in the search for novel therapeutic targets 
(Enkner, Pichlhofer et al. 2017). Nonsynonymous mutations were identified in TCs by 
cancer gene sequencing of ALK, ATM, CDKN2A, ERBB4, FGFR3, KIT, NRAS and 
TP53. Fluorescence in situ hybridization (FISH) detected gene deletions of CDKN2A, 
TP53 and ATM in TCs, but not in type A thymomas. Differences between TCs and type 
A thyomomas in total microRNA were detected by sequencing (e.g.C19MC microRNA 
cluster highly expressed in type, but silenced in TC). Immunohistochemistry showed in-
creased PDGFRA in TCs and PD-L1 in type B3 and TCs. The identified differences in 
cancer gene mutations and differential microRNA expression between type B3 and A 
thymomas and TCs may spark new developments in drug development (Enkner, 
Pichlhofer et al. 2017). 
The genome of TETs was explored in with a muli-omic platform participating in the “The 
Cancer Genome Atlas”. The gene GTF2I showed a high mutational frequency (39%) in 
WHO type A ad AB thymomas. Other recurrent somatic mutations at a lower frequency 
were described for the genes of HRAS, TP53 and NRAS. The clonality of all four signifi-
cantly mutated genes suggested their involvement in early thymic cancer development 
(Radovich, Pickering et al. 2018). The multi-omics approach could define four robust 
molecular types of TETs associated with differing survival outcome and revealed that 
thymomas have the lowest mutational burden of all investigated cancers in adults. The 
authors suggested that future drug development based on the advances in genomic 
knowledge of the project will have an impact on TET management (Radovich, Pickering 




2.6 Screening, symptoms, diagnosis and progno-
sis 
2.6.1 Screening 
In patients with paraneoplastic syndromes, particularly MG, screening for thymomas is 
recommended by chest CT (followed by FDG-PET) or integrated FDG-PET/CT 
(Titulaer, Soffietti et al. 2011).  
2.6.2 Symptoms 
TETS can present as an incidental finding in asymptomatic people undergoing screening 
investigations or during radiological workup (Chest X-ray (CXR) or computed tomogra-
phy (CT)) for unrelated symptoms or disorders. TETs can present symptoms due to local 
compression of (thoracic) organs or systemic symptoms from TET associated parane-
oplastic diseases.  
Local symptoms arising from TETs that are typically located in the bed of the thymus 
from compression and/or invasion of adjacent thoracic organs (e.g. cough, dyspnea, chest 
pain). Rare symptoms are superior vena cava syndrome from direct mediastinal mass 
compression of the superior caval vein or diaphragmatic paralysis due to phrenic nerve 
invasion/compression. 
Thymomas may manifest with a characteristic growth pattern along the serous mem-
branes in the chest cavity, the pleura and the pericardium. Pleural and pericardial effu-
sions cause local symptoms and are a sign of more advanced disease. 
2.6.3 Diagnosis 
A preoperative biopsy is obtained in cases of suspicion of lymphoma, germ cell tumors, 
mediastinal metastasis and patients with suspicion of advanced TETs with infiltration on 
potentially resectable structures for planning of neoadjuvant therapy. In MG patients with 
a high suspicion for thymomas surgery is planned without the need for a biopsy.  
2.6.4 Imaging 




Forty-five to 80% of thymomas were reported to be visible on CXR (Marom 2010) ( See 
Figure 3). Any anterior mediastinal mass identified on CXR has to be further character-
ized by CT. Patients with clinical suspicion for thymoma and normal CXR will have a 
CT scan because of higher sensitivity (Marom 2010). 
 
Figure 3: Chest X-ray of ADC of the thymus. Adopted from (Moser, Schiefer et al. 2015). 
 
Computed tomography (CT)  
CT is the preferred imaging modality for diagnosis and assessment of resectability for 
patients with TETs (See Figure 4).  Intravenous contrast agents are essential for preoper-
ative staging and assessment of resectability of invasive tumors (e.g. vessel infiltration) 
(Marom 2010). Standard report terms for chest CT findings of anterior mediastinal 
masses suspicious for thymomas were defined by ITMIG (Marom, Rosado-de-
Christenson et al. 2011). 
 
Figure 4: Computed tomography of ADC of the thymus. Adapted from (Moser, Schiefer et al. 2015). 
 
In a retrospective study of 133 patients with thymoma who underwent surgical resection 
(1997-2010) 23 patients (17%) had an incomplete surgical resection. Several preoperative 
CT imaging characteristics predicting respectability were identified: lobulated tumor con-
tour, ≥50% abutment of vessel circumference, thoracic lymphadenopathy, lung changes, 
pleural nodularity, larger tumor size (mean 9.7 cm). On multivariable analysis only de-






incomplete resection. The authors concluded that CT can predict the probability of com-
plete surgical resection and might help identify patients benefiting from neoadjuvant 
treatments (Hayes, Huang et al. 2014).  
In a retrospective study on 84 patients with thymoma (1986-2007) associations between 
computed tomography features of thymomas and their pathological classification 
(Masaoka-Koga) were reported (Ozawa, Hara et al. 2016). Stage III-IV thymomas were 
of larger size, displayed a more irregular shape or contour, and necrosis and calcification 
were more prevalent than in stages I-II. WHO B2 an B3 type thymomas showed irregular 
contour and shape, invasion of: mediastinal fat, great vessel, pericardium or lung  more 
often than WHO type A, AB or B1 thymomas.  
Magnetic resonance imaging (MRI) 
MRI has no radiation toxicity but is not recommended for mediastinal masses with un-
known etiology because it provides poor resolution of pulmonary parenchyma. It may be 
employed to assess vessel invasion with or without intravenous contrast agents (Marom 
2010). 
18Fluorine-fluorodeoxyglucose–positron emission tomography  (FDG-PET) 
In a retrospective study on 94 patients with anterior mediastinal nodules or masses 
PET/CT maximum standard uptake value  (SUVmax) was found to discriminate thymomas 
from TC, diffuse large cell B cell lymphoma and Hodgkin lymphoma. The authors sug-
gested that a tumor tissue biopsy should be obtained in cases of SUVmax ≥ 7.5 to possibly 
select patients with TC for neoadjuvant therapy and to avoid futile resections in 







Figure 5 SUVmax of anterior mediastinal tumors. Distribution of SUVmax (FDG-PET CT) of patients with 
anterior mediastinal tumors. From (Watanabe, Shimomura et al. 2019). *p < 0.05, ***p < 0.005, 
****p < 0.001 
 
Conflicting data regarding the use of SUVmax to distinguish thymoma WHO types were 
reported (Shibata, Nomori et al. 2009, Otsuka 2012, Watanabe, Shimomura et al. 2019). 
FDG-PET CT SUVmax may aide in detecting local invasiveness of thymomas but SUVmax 
cut-offs for Masaoka-Koga or TNM stage could not be defined (Luzzi, Campione et al. 
2009, Otsuka 2012, Watanabe, Shimomura et al. 2019). In an ITMIG prospective data-
base with FDG-PET data of 154 patients SUVmax was reported to predict histologic type 
and pathologic Masaoka-Koga stage; ROC analysis: area under curve: 0.79; p < 0.001 
and 0.81; p < 0.001, respectively (Korst, Fernando et al. 2017). 
In a study of 27 patients with advanced or recurrent TETs response to chemotherapy was 
assessed by 18F-FDG PET-CT according to RECIST criteria (Response Evaluation Cri-
teria in Solid Tumor). Percent change of SUVmax in before and after treatment 18F-FDG 
PET-CT correlated with morphovolumetric response (r = 0.64, p = 0.001). Percent change 
of SUVmax of -25% was reported to discriminate responders from non-responders (sen-
sitivity of 88% and a specificity of 80%) (Segreto, Fonti et al. 2017). 
Of additional value are 68Gallium labeled somatostatin (SST) analogues and so-
matostatin receptor scintigraphies to evaluate further therapeutic modalities in patients 
not responding to therapy (Imbimbo, Ottaviano et al. 2018). 68Ga-SST-analogues PET/CT 
and 18F-FDG-PET/CT showed concordance in 43% of 39 patients with metastasized 
TETs. In only 5% of patients there was additional information when 68Ga-SST-analogues 
PET/CT was positive and 18F-FDG-PET/CT was negative (Sollini, Erba et al. 2014). 
2.7 Tumor staging  systems 
Over time diffenent staging systems for patients with TETs have evolved (International 
Association for the Study of Lung Cancer 2016). A widely used staging system that was 
used for all studies in this thesis is the Koga modification (Koga, Matsuno et al. 1994) of 
the Masaoka (Masaoka, Monden et al. 1981) stage classification. Stage definitions for the 
Koga modification of the Masaoka system (from now on termed Masaoka-Koga) are de-





Table 4: Masaoka-Koga staging sytem. Adapted from Koga et al. and Detterbeck et al (Koga, Matsuno et 
al. 1994, Detterbeck, Nicholson et al. 2011).  
I  Grossly and microscopically completely encapsulated tumor 
IIa  Microscopic transcapsular invasion 
IIb  
 
Macroscopic invasion into thymic or surrounding fatty tissue, or grossly adherent to but not 
breaking through mediastinal pleura or pericardium 
III  Macroscopic invasion into neighboring organ (i.e., pericardium, great vessel, or lung) 
IVa  Pleural or pericardial metastases 
IVb  Lymphogenous or hematogenous metastasis 
 
Although the Masaoka-Koga staging system was the most widely used staging system for TETs, more than 
15 different classification systems were in use to stage patients with TETs (Filosso, Ruffini et al. 2014). In 
an effort to create one official stage classification for TETs, the Union for International Cancer control 
(UICC) and the American Joint Committee on Cancer (AJCC) have reviewed a retrospective database in-
cluding data of 10,808 patients collected by the International Thymic Malignancies Interest Group (ITMIG) 
and International Association for the Study of Lung Cancer (IASLC) in order to develop a new TNM Clin-
ical Classification for TETs (see  
Table 5) (Detterbeck, Stratton et al. 2014, Filosso, Ruffini et al. 2014, Kondo, Van Schil 
et al. 2014, Nicholson, Detterbeck et al. 2014, Carter, Benveniste et al. 2017).  
 
Table 5: IASLC/ITMIG TNM (8th edition) categories and stage. Adapted from the Staging Manual in Tho-
racic Oncology, Second Edition, An International Association for the Study of Lung Cancer Publication 
(International Association for the Study of Lung Cancer 2016). 
TX  Primary tumor cannot be assessed. 
T0  No evidence of primary tumor 
T1  Tumor encapsulated or extending into the mediastinal fat, may involve the mediastinal pleura. 
T1a  No mediastinal pleural involvement 
T1b  Direct invasion of the mediastinal pleura 
T2 Tumor with direct involvement of the pericardium (partial or full thickness). 
T3  Tumor with direct invasion into any of the following; lung, brachiocephalic vein, superior vena 
cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or vein. 
T4  Tumor with direct invasion into any of the following; aorta (ascending, arch or descending), arch 
vessels, intrapericardial pulmonary artery, myocardium, trachea, or oesophagus 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in anterior (perithymic) lymph nodes 
N2  Metastasis in deep intrathoracic or cervical lymph nodes 
M0  No pleural, pericardial or distant metastasis 
M1  Distant metastasis 
M1a  Separate pleural or pericardial nodule(s) 
M1b  Distant metastasis beyond the pleura or pericardium 
 
Stage I  T1 N0 M0 
Stage II  T2 N0 M0 
Stage IIIA  T3 N0 M0 
Stage IIIB  T4 N0 M0 




 Any T N0, N1 M1a 
Stage IVB  
 
Any T  
Any T  
N2  
Any N  
M0, M1a  
M1b 
 
A lymph node map was proposed by ITMIG (Detterbeck, Stratton et al. 2014, Carter, 
Benveniste et al. 2017). The new N descriptor distinguishes the anterior region (N1), in-
cluding prevascular, para-aortic, ascending aorta, superior and inferior phrenic, supradi-
aphragmatic, and low anterior cervical lymphnodes from the deep region (N2), including 
internal mammary, upper and lower paratracheal, subaortic, subcarinal, hilar, lower jug-
ular and supraclavicular lymph nodes.  
The ESMO Clinical Practice Guidelines 2015 recommend the routine removal of N1 
nodes (anterior mediastinal and anterior cervical). A systematic lymphadenectomy of N1 
and N2 nodes is only recommended for TC histology which presents with higher rates of 
lymphatic metastases than thymomas (20% vs. 3%) (Girard, Ruffini et al. 2015). 
 
The comparison of OS staged according to the Masaoka-Koga and TNM system is de-
picted in Figure 6. 
  
 
Figure 6: OS of patients with any R resection in different stage by the Masaoka-Koga or the 8th edition 
TNM staging (Kaplan-Meier survival curves: log-rank test). Adopted from (Liang, Gu et al. 2016). 
 
The Masaoka-Koga and IASLC/ITMIG TNM (8th edition) are displayed side by side in 





Table 6: Relationship between IASLC/ITMIG TNM (8th edition) categories and Masaoka-Koga staging 
system. Adopted from (Liang, Gu et al. 2016). 
TNM 
Stage 
TNM Definition (involvement of) Masaoka-Koga 
 
Stage I T1aN0M0 Encapsulated or unencapsulated, with or without 
extension into mediastinal fat 
Stage I and II 
 
 T1bN0M0 Extension into mediastinal pleura Stage III (partial-pleura) 
Stage II T2N0M0 Pericardium Stage III (partial-pericar-
dium) 
Stage IIIa T3N0M0 Lung, brachiocephalic vein, superior vena cava, 






Stage IIIb T4N0M0 Aorta, arch vessels, main pulmonary artery, 




Stage IVa TxN1M0 Anterior (perithymic) nodes Stage IVb 
 TxN0M1a Separate pleural or pericardial nodule(s) Stage IVa 




Stage IVb TxN2M0 Deep intrathoracic or cervical nodes  Stage IVb 
 TxN2M1a Deep intrathoracic or cervical nodes, Separate 
pleural or pericardial nodule(s)  
Stage IVb 




2.8 Definition of TET recurrences 
Recurrences of TETs can occur after all disease was eradicated (after R0 Resection or Radiographic Com-
plete Response). Classification of recurrences in local, regional and distant was followed as recommended 
by ITMIG (see  
Table 7) (Huang, Detterbeck et al. 2011).  
 
Table 7: ITMIG Definitions of TET recurrence. Adopted from (Huang, Detterbeck et al. 2011). 
Local recurrence—anterior mediastinum 
 TET occurring in bed of thymus or previously resected TET 
 Includes pericardial, pleural, or pulmonary tumor that is immediately adjacent to the thymus or previously 
resected TET 
 Lymph nodes immediately adjacent to the thymus or previously resected TET (including nodes in the neck 
immediately adjacent to the upper poles of the thymus) 
 Recurrence at the site of a previous noncontiguous metastasis (stage IVa) 
Regional recurrence—intrathoracic recurrence not contiguous with thymus or previous thymoma 
 Parietal or visceral pleural nodules 
 Pericardial nodules 
 Mediastinal lymph nodes not adjacent to the normal thymus or the previous TET 
Distant recurrence 
 Extrathoracic recurrence 




2.9 Treatment of TETs 
The following descriptions on TET treatment are focused but not limited to the treatment 
of patients undergoing surgery. All studies in this thesis were performed on TET patients 
who underwent surgical resection with or without multimodal therapies. 
2.9.1 National and international Consensus statements 
Different countries have formulated national expert consensus guidelines for the treat-
ment of patients with TETs. Exemplary, the French and Italian efforts are briefly ex-
plained. In 2012 in France a nationwide network named RYTHMIC (Réseau tumeurs 
THYMiques et Cancer) for the management and research on patients with TETs was 
initiated by the French National Cancer Institute. A central pathologic review of all TET 
specimens as well as a tumor board discussion of all patients are central components of 
the French network (Hadoux, Girard et al. 2012). In the recent past many national efforts 
directed at improving patient care for those diagnosed with TETs emerged. In 2014 in 
Italy a network called TYME (ThYmic MalignanciEs was founded (Imbimbo, Ottaviano 
et al. 2018). An expert consensus of 66 multi-disciplinary specialists from 27 Italian cen-
tres for the management (diagnosis and treatment) of TETs in Italy was published 
(Imbimbo, Ottaviano et al. 2018).  
Other national efforts include the Chinese Alliance for Research in Thymomas (ChART) 
registry (Wang, Pang et al. 2016) or the Japanese Association for Research on the Thymus 
(JART) (Okuda, Yano et al. 2014).  
International efforts of the ESTS Thymic working group (Ruffini, Falcoz et al. 2018) and 
ITMIG (Detterbeck 2013) have established large thymic databases necessary to establish 
guidelines based on higher quality evidence. 
2.9.2 Management algorithm: resectable disease 
The 2015 ESMO (European Society for Medical Oncology) clinical practice guidelines 
for patients with resectable TETs (European Society for Medical Oncology) is depicted 





Figure 7: Treatment algorithm for resectable thymic tumour (Masaoka-Koga stage I–III, TNM stage I–
IIIA). From: Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up (14). 
 
2.9.3 Institutional treatment specifics 
There are no randomized controlled clinical multicenter trials on the treatment of TETs. The current medical 
evidence is mostly based on retrospective single center experiences and population studies. Thus the peer-
reviewed literature cannot give definitive recommendations for patient care. We recommend that all cases 
undergo multidisciplinary tumor board review. The treatment scheme applied for TET patients is based on 
the experience gained from our thoracic surgery center, a multidisciplinary consensus of thoracic surgeons, 
oncologists, radiotherapists, and pathologists (see  








Table 8: Therapeutic algorithm at the Division of Thoracic Surgery, Medical University Vienna (Moser, 
Scharitzer et al. 2014). 
     WHO type  
stagea 
A, AB, B1  B2, B3 Thymic carcinoma  
I  -  -  -  
II  -  -  adjuvant therapy? 
III  nCRT  nCRT  nCRT  
IV  nCRT  nCRT  nCRT  
nCRT neoadjuvant Chemo- and/or radiotherapy 
aMasaoka-Koga stage 
 
The institutional treatment algorithm stipulates a multimodal therapy regimen for patients 
in Masaoka–Koga stages III and IV. For TCs neoadjuvant or adjuvant therapy is discussed 
also in stage II patients. Standard chemotherapy for either neoadjuvant or adjuvant chem-
otherapy consists of three cycles of cisplatin 50 mg/m2, doxorubicin 50 mg/m2, and cy-
clophosphamide 500 mg/m2 (PAC chemotherapy). Individualized radiation therapy in an 
adjuvant or neoadjuvant setting is applied with doses up to 50 to 60 Gray. For definitive 
staging and histology the histopathological examination of the operative TET specimen 
is reqired. All TET specimens are reviewed by the reference pathology at the Faculty of 
Mannheim, University of Heidelberg, Germany (second opinion). Decisions on postop-
erative RT (PORT) or adjuvant ChT are based on pathological staging. 
2.9.4 Surgery 
If a complete TET resection (R0) is deemed feasible upfront surgery is indicated. This is 
usually the case in Masaoka-Koga stages I and II, as well as stage III with invasion of 
structures that are readily resectable (e.g. pericardium, adjacent mediastinal pleura or 
lung). In this Chapter different surgical approaches to TETs, the rationale for extended 
thymectomy and surgery for TETs with pleural involvement are detailed.  
2.9.4.1 Surgical approach: open vs. minimally invasive 
A variety of different open and minimally-invasive surgical approaches for the resection 
of TETs are in use. The open approaches are: thoracotomy, sternotomy, hemiclamshell 
and clamshell and cervical incisions. Minimally-invasive techniques include various 
modifications of VATS and robotic surgery (RATS) (Figure 8). Minimally-invasive tech-
niques are established as the treatment standard for early-stage TETs (Masaoka-Koga 




Manoly, Whistance et al. 2014, Friedant, Handorf et al. 2016). All the oncological prin-
ciples that are followed in open standard thymic surgery have to be met. There are no 
signs that minimally-invasive procedures are inferior to open surgery considering com-
plications, recurrence rates or survival. The reported advantages of minimally-invasive 
surgery are shorter length of hospital stay, less intraoperative blood loss and improved 
cosmetic results (Ruffini, Filosso et al. 2018). The state of the art of thymic minimally 
invasive surgery across Europe (Matilla, Klepetko et al. 2017) as well as our initial expe-
rience with a combined sequential left-sided and subxiphoid video-assisted thoracic sur-
gery approach for resection of large anterior mediastinal tumors (Matilla JR 2018) was 




Figure 8: Surgical approach. Open surgery: through (A) cervical incision for basic thymectomy. Cervical 
thymectomy: The two thymic horns are developed through a cervical incision. The part of the surgical 
thymus shown in the photograph is called basic thymectomy.  Left-sided thoracotomy for resection of thy-
moma ((B) arrow heads), VATS thymectomy (C),   Robotic thymectomy (D). Photographs A-D from the 







Rationale for extended thymectomy 




Figure 9: Surgical anatomy of the thymus. (black,thymus; gray, fat, which may contain islands of thymus 
and microscopic thymus). From (Sonett and Jaretzki 2008). 
 
Thymomectomy is the removal of the thymoma/TC without removal of the thymus. Ex-
tended thymectomy is the removal of all mediastinal fatty tissue between the phrenic 
nerves along with basic thymectomy. While extended thymectomy is the treatment of 
choice for patients with myasthenia gravis its role in thoracic surgery for patients with 
thymomas without MG is still a matter of debate. The rationale to perform extended thy-
mectomy in patients with MG with and without TETs is to completely remove all thymic 
tissue that is dispersed within the mediastinal fatty tissue (see Figure 9 and Figure 10) 
(Masaoka, Nagaoka et al. 1975, Sonett and Jaretzki 2008). Extended thymectomy for MG 
is supported by improvements in MG disease activity in patients with residual thymus 
undergoing extended thymectomy after failure to improve after basic or non-radical thy-
mectomy (Masaoka and Monden 1981, Jaretzki, Penn et al. 1988). In cases of patients 
with TETs without MG current recommendations advocate an extended thymectomy in 
conjunction with the resection of the TET (Ruffini, Filosso et al. 2018). In support of this 
more radical approach are the risk of multiple TETs, risk of local recurrences, risk of 




whether the TET is encapsulated and the difficulty to achieve tumor-free resection mar-





Figure 10: Extended thymectomy. Representative CT sections with the corresponding operative specimens 
of  extended thymectomies (picture from the division of thoracic surgery, Medical University Vienna) of 
(A and C) a patient with MG (Osserman II-b): cervikal & left VATS approach; thymoma - WHO type B2 
Masaoka II-1, R0 (B) (B and D) Incidental finding during preoperative radiological workup strumectomy); 
thoracotomy; thymoma WHO type AB, Masaoka II-1, R0, no MG; follicular thymitis; 
2.9.4.2 Treatment of TETs with pleural involvement 
For lower stages of TETs complete surgical resection has become the accepted treatment 
standard. Patients with advanced-stage TETs presenting with pleural or pericardial dis-
semination (Masaoka-Koga Stage IVA (Koga, Matsuno et al. 1994)) are encountered in 
only 6.8% of all patients with TETs (Koga, Matsuno et al. 1994, Kondo and Monden 
2003, Murakawa, Karasaki et al. 2015). Because of the scarcity of existing data in cases 
with TETs with pleural disease the value of surgical resection remains in question. There 
are several reasons for low case numbers: TETs with pleural involvement are usually 
treated in single institutions. Also, there is a wide array of different forms of clinical 
presentation. While some patients are diagnosed with one or few well defined and local-








of patients presents the combination of pleural and pulmonary tumor spread. Depending 
on the disease distribution several surgical techniques were developed for resection: ex-
trapleural pneumonectomy (EPP), total pleurectomy (TP) or local pleurectomy (LP). All 
of the surgical approaches are frequently combined with ChT and/or RT (Ishikawa, 
Matsuguma et al. 2009, Fabre, Fadel et al. 2011). EPP will be performed for numerous 
visceral pleural, parietal pleural and pericardial implants (and pulmonary nodules) that 
cannot be locally resected (Wright 2011). TP removes all parietal (Figure 11), mediastinal 
and diaphragmatic pleural surfaces and pericardium with or without resection of the dia-
phragm. Therefore TP is performed when visceral pleura and lung are not affected by 
malignant disease. LP is the local resection of pleural implants without removal of all 
pleural surfaces (metastasectomy) and is performed for mono- or oligometastatic disease. 
Pleurectomy/decortications (P/D) is a lung sparing procedure with the intent of removing 
all macroscopic disease in order to prolong patient survival. It is a TP of the parietal and 
visceral pleural surfaces (Imanishi, Nabe et al. 2018). Extended P/D (EPD) includes re-
section of diaphragm and pericardium in addition to P/D (Bilancia, Nardini et al. 2018, 
Imanishi, Nabe et al. 2018).  In patients with Masaoka-Koga stage IVa (pleural or peri-
cardial metastases) current recommendations include major pleural surgery with curative 
intent such as P/D or EPP usually performed as part of multimodal therapy (Ruffini, 
Filosso et al. 2018). 
 
 
Figure 11: Pleural metastases of WHO type B2 thymoma. Representative CT scan section  of the regional 











There is an ongoing debate on wheter debulking (reduction in tumor volume) for not 
completely resectable tumors has a role in TET surgery. Debulking surgery may be indi-
cated in patients where resection can alleviate cardiopulmonary compromise (see Figure 
12) in order to facilitate systemic treatments or RT. Debulking may reduce the number of 
local recurrences (Mornex, Resbeut et al. 1995) and reduce radiation field sizes of adju-
vant RT (Attaran, Acharya et al. 2012). In cases of reoperation for recurrent thymomas 
debulking surgery should be limited to selected patients with no other available treatment 
options (Dai, Song et al. 2015). 
 
Figure 12:  Magnetic resonance image (A) of a not completely resectable TC. Because of upper inflow 
occlusion and severe compromise of cardiorespiratory function the patient was not amenable to ChT. After 
incomplete resection of the TC regular cardiopulmonary conditions allowed adjuvant ChT (postoperative 
chest X-ray (B)). From (Moser and Klepetko 2013). 
2.9.5 Systemic therapy 
In patients with unresectable disease (distant metastases or technical unresectability, e.g. 
extensive infiltration of cardiac ventricles) or those unfit for surgery or anasthesia because 
of  comorbidities may undergo individualized therapy. The patients`performance status, 
tumor stage or symptoms will influence decisions regarding the use RT, chemo- or 
chemoradiotherapy, or other systemic treatments. As all studies in this thesis were done 
on patients undergoing surgical resection the following sections will focus on systemic 
or radiation therapy with regard to patients undergoing surgery for TETs. 
2.9.5.1 Chemotherapy (Cht) 
ChT has a role in patients with unresectable disease, as neoadjuvant or adjuvant therapy 





In cases of TET invasion of potentially resectable structures (e.g. superior vena 
cava, aortic arch) when upfront surgery is in doubt to achieve R0 resection borders neo-
adjuvant therapy should be considered in order to increase the probability for a complete 
resection. In a metaanalysis evaluating the effect of induction therapy (cisplatin based 
ChT) and surgery on OS of patients with advanced TETs reported a pooled response rate 
of induction therapy of 59%, a pooled rate of complete resection of 73% and pooled 5- 
and 10-year OS following induction therapy confirming favorable outcomes of this ap-
proach (Hamaji, Ali et al. 2015). The highest response rates (70-81%) with neoadjuvant 
ChT were reported with platinum-based ChT combined with anthracycline (Loehrer, 
Chen et al. 1997, Berruti, Borasio et al. 1999, Kim, Putnam et al. 2004, Chau, Kim et al. 
2010).  
PAC ChT for 29 patients with metastatic or recurrent thymoma (intergroup trial) showed 
three complete responses (CRs) and 12 partial responses (PRs): rate of combined CR+PR: 
50% (Loehrer, Kim et al. 1994). Combinations of platinum based ChT without anthracy-
cline were reported with inferior response rates: 32-56% (Giaccone, Ardizzoni et al. 1996, 
Loehrer, Jiroutek et al. 2001, Chau, Kim et al. 2010, Lemma, Lee et al. 2011) but are an 
option for patients who cannot undergo the most aggressive regimens. ChT with single 
agents was inferior to the combinations of several chemotherapeutic agents (Chau, Kim 
et al. 2010). A vast array of second-line chemotherapeutic approaches were undertaken 
for progression of disease with first line ChT (e.g. pemetrexed (Gbolahan, Porter et al. 
2018), ocreotide (Loehrer, Wang et al. 2004)). The role of chemotherapy in advanced 
TETs was recently reviewed (Schmitt and Loehrer 2010). 
2.9.5.2 Novel systemic therapies: targeted therapy and immuno-
therapy 
The recent experience with immune checkpoint inhibitor therapy (Brown, Dorfman et al. 
2003, Merveilleux du Vignaux, Maury et al. 2017, Badiyan, Roach et al. 2018, Saleh, 
Khalifeh-Saleh et al. 2018, Yokoyama and Miyoshi 2018) and the use of targeted thera-
pies for patients with TETs was comprehensively reviewed (Berardi, De Lisa et al. 2014, 
Ried, Marx et al. 2016). 
KIT is a potential target in TCs 
KIT mutations are present in up to 12% of TCs (Schirosi, Nannini et al. 2012) . In patients 




testing for c-kit is recommended. Several therapeutic possibilities were described as for 
example imatinib for mutated exons 9 and 11, sunitinib for mutated exons 13, 14 or so-
rafenib for mutated exon 17 (Schirosi, Nannini et al. 2012). 
Immune checkpoint inhibitor therapy for TCs 
Forty patients with recurrent TC progressing after ChT were treated with pembrolizumab, 
monoclonal antibody with specificity for PD-1 (single-arm phase 2 study), showed 22.5% 
objective reponses, including one complete reponse. Despite the observation that TC pa-
tients are not typically affected by paraneoplastic autoimmune disorders, a high rate of 
immune-related events (e.g. myocarditis) was reported (Giaccone, Kim et al. 2018). 
2.9.6 Radiation therapy (RT) 
Treatment recommendations regarding RT for TETs are mostly based on data of small 
patient cohorts collected over long periods of time and population-based studies (Fuller, 
Ramahi et al. 2010). The indications for RT as part of a multimodal approach as well as 
the optimal protocols for different treatment situations remain a matter of debate. All 
cases should be discussed in a multidisciplinary tumor board.  
In the following treatment situations of patients with TETs there is a role for RT: 
 unresectable disease (also progressive disease during neoadjuvant ChT) 
 following incomplete resections of TETs (R1 or R2 resections). 
The role of RT with regards to tumor stage was recently reviewed (Fuller, Ramahi et al. 
2010). Postoperative radiation therapy (PORT) should be considered for patients after 
complete surgical resection of Masaoka-Koga stage II-IV TETs (ESMO guidelines) 
(Girard, Ruffini et al. 2015). RT is currently not recommended in Masaoka-Koga stage I 
after complete resection. One reason is the low frequency of recurrences. In stage I thy-
momas undergoing complete resections and followed-up for 32 years recurrence rates 
were reported with 2-3%  (Awad, Symmans et al. 1998). Another reason is the lack of 
benefit of PORT in stage I studies. In a Chinese prospective study on 29 patients that were 
randomized to postoperative radiotherapy for stage I thymomas no survival benefit for 
either group was detected: 10-year OS: resection plus RT 88% vs. resection alone 92% 
(Zhang, Lu et al. 1999). The role of PORT after complete resection in stage II thymoma 




tumour (Masaoka-Koga stage I–III, TNM stage I–IIIA). Several retrospective center ex-
periences do not recommend PORT in this situation (Mangi, Wright et al. 2002, Rena, 
Papalia et al. 2007, Chen, Feng et al. 2010, Berman, Litzky et al. 2011). A meta-analysis 
including seven retrospective studies (1724 patients with primary thymoma) found a po-
tential OS benefit of PORT for patients with locally advanced thymomas (Masaoka-Koga 
stages III and IV) after macroscopically complete resection compared to surgery alone. 
In this analysis PORT did not convey a survival benefit in stage II patients (Lim, Kim et 
al. 2016). TCs present in higher stages than thymomas and are accompanyied by lym-
phatic or hematogeneous metastases in 10-30% (Kondo and Monden 2003, Ruffini, 
Detterbeck et al. 2014, Hamaji, Shah et al. 2017). A Meta-Analysis of PORT for TC (7 
retrospective observational studies, 786 patients) supports PORT for TC (recommenda-
tions regarding stage and resection status could not be provided) (Hamaji, Shah et al. 
2017). 
 
2.10 Prognostic factors for patients with TETs 
2.10.1 Outcome measures for TETs 
Overall survival (OS) is an adequate standard outcome measure for many cancers, espe-
cially when survival after recurrence is short and the cause of death is the particular can-
cer. In the case of thymomas many patients die of causes other than thymomas (see Figure 
13) and many patients experiencing a thymoma recurrence have a long life expectancy 
(Huang, Detterbeck et al. 2011). Because of the indolent behavior of especially early stage 
thymomas, freedom from recurrence (FFR) reflects best the biology of these tumors after 
curative treatment. In addition to OS, CSS should be reported because it reflects death 
from thymoma/TC. The analysis of Time-to-progression (TTP) is recommended for pa-
tients with residual disease, although the outcome of this patient population is well re-
flected in the analysis of OS (Huang, Detterbeck et al. 2011). Another issue concerning 
survival analysis is the increased risk of thymoma patients to develop and die from ex-





Figure 13: Overall cause of death after resection of thymomas. From (Huang, Detterbeck et al. 2011). 
 
This is a brief description of the outcome measures recommended by ITMIG (Huang, 
Detterbeck et al. 2011) and ESTS Thymic Working group (Ruffini, Detterbeck et al. 2014, 
Ruffini, Detterbeck et al. 2014) that were used in this thesis. OS was calculated as the 
primary outcome from the date of surgery to the date of death of any cause (censored 
observations: patients at the last time point known to be alive). The end-point of interest 
for Cause-specific survival (CSS) was defined as death from TET (censored observations: 
unrelated deaths and unknown cause of death) (Huang, Detterbeck et al. 2011). FFR was 
calculated only in patients after complete surgical resection (R0) from the date of first 
pleural surgery to the date of recurrence in patients with full information on recurrence 
status (Ruffini, Detterbeck et al. 2014). Disease-free survival (DFS) was analyzed from 
the date of surgery to the date of recurrence or death from any cause (Ruffini, Detterbeck 
et al. 2014). For the determination of time to progression only patients after incomplete 
resection (R1 or R2) or patients with partial remission or stable disease after chemother-
apy and/or radiotherapy were included (Huang, Detterbeck et al. 2011). Figure 14 depicts 
estimated outcomes for stage III thymomas when different outcome parameter definitions 





Figure 14: Comparison of different oucome measures after resection of stage III thymomas. From (Huang, 
Detterbeck et al. 2011). 
2.10.2 Pathological predictors of treatment outcome  
The most widely accepted prognostic factors for the treatment of patients with TETs are 
completeness of resection, Masaoka–Koga stage (discussed in section 2.7), and WHO 
histological type (discussed in section 2.3) (Chen, Marx et al. 2002, Detterbeck and 
Parsons 2011, Ruffini, Filosso et al. 2011, Venuta, Rendina et al. 2011, Ruffini, 
Detterbeck et al. 2014, Ruffini, Detterbeck et al. 2014).  The WHO histological classifi-
cation for TETs with regard to the different thymoma types is still a matter of intense 
discussion with respect to prognosis (Guerrera, Rendina et al. 2015).  
In a Korean study including 1597 patients (2000-2013) undergoing resection of 
TETs with 446 patients undergoing “intentional” lymphnode dissection, lymph node me-
tastasis was identified in 20 (6.7%) of 298 patients with thymoma and 47 (31.7%) of 148 
patients with TC. TC (HR:19.2, p<0.001) and tumor size (HR:1.09, p=0.02) were signif-
icant predictive factors for lymph node metastasis at multivariable analysis. The 10-year 
FFR of pN1/pN2 was significantly worse than that of pN0 (p<0.001), but 10-year FFR 
for intentional lymph node dissection was not superior to the group without intention 
lymph node dissection (82.4% versus 80.9%, p=0.46 in thymoma; 45.7% versus 44.0%, 
p=0.42 in TC) (Hwang, Kang et al. 2018). 
2.10.3 Experimental biomarkers for TETs 
Sparked by our findings of the involvement of the receptor for advanced glycation end-
products (RAGE) in antigen-specific T cell expansion (Moser, Desai et al. 2007) we iden-
tified both soluble (s) receptors, sRAGE and endogenous secretory (es)RAGE to be sig-
nificantly reduced in serum of patients with MG without TETs (Moser, Bekos et al. 2012). 
Further work  identified a role of the experimental molecules RAGE and its ligand high 
mobility group box 1 (HMGB1) in thymic physiology and pathology of TETs. Tumor 
tissue expression of RAGE was most intense in WHO type B2 thymomas and TCs. 
HMGB1 nuclear staining was strongest in types A and AB, conversely to its cytoplasmic 
staining intensities: A and AB (none), B1 (strong), B2 (moderate), B3 and TC (weak). 
Serum concentrations of soluble RAGE were significantly reduced in patients with TETs; 




in TH and TETs, HMGB1 was specifically elevated in TETs indicating diagnostic poten-
tial. (Moser, Janik et al. 2014). 
Also, our group recently revealed a prognostic role of heat shock proteins (HSPs) for 
patients with TETs. HSPs were differentially expressed in WHO histologic types and 
pathological Masaoka-Koga tumor stages. Weak HSP tumor expression correlated with 
worse FFR. HSP serum concentrations were elevated in TETs and MG, correlated with 
clinical tumor stage and histologic subtype and decreased significantly after complete 
tumor resection (Janik, Schiefer et al. 2016). 
Also recently described was the expression profile for three long non-coding RNAs 
(AFAP1-AS1, LINC00324, and VLDLR-AS1) to independently predict RFS among thy-
moma patients (Gong, Jin et al. 2018). Overexpression of cytotoxic T Lymphocyte Anti-
gen 4 (CTLA-4 or CD152) significantly correlated with reduced OS in thymoma patients 
and in atypical thymomas (Santoni, Amantini et al. 2018). 
2.11 Introduction to the biomarkers of the thesis 
There is a growing body of evidence for the concept of inflammation being a significant 
part of tumor progression. Chronic inflammation in tumor microenvironments is thought 
to propagate tumor survival and proliferation (Coussens and Werb 2002, Korniluk, Koper 
et al. 2017). 
Circulating biomarkers that are modulated in response to cancer-related inflammation 
may serve as powerful diagnostic and/or prognostic tools for TETs. For this PhD thesis 
we investigated a series of serum/plasma components and indices from peripheral blood 
derived cells of the innate and adaptive immune system or platelets: CRP, fibrinogen, 
neutrophil-to-lymphocyte ratio (NLR), and the platelet-to-lymphocyte ratio (PLR) in pa-
tients with TETs. 
2.11.1 C-reactive protein (CRP) 
CRP is a pentraxin family member with pentameric structure (see Figure 14) (Volanakis 





Figure 15: Human CRP. The pentameric disc-like structure face-on and side-on (arrows) in a negatively 
stained electron micrograph. From (Pepys and Hirschfield 2003). 
 
Triggered by proinflammatory cytokines: interleukin (IL)-6, IL-1β and tumor necrosis 
factor alpha (TNFα-), it is produced by hepatocytes during the acute phase response 
(Gabay and Kushner 1999). With a constant half-life of 19 hours in plasma in health and 
disease, CRP plasma concentrations are a direct reflection of its synthesis rate (Vigushin, 
Pepys et al. 1993). Therefore the concentration circulating CRP in plasma (or serum) 
correlates directly with the intensity of the physiological or pathological stimuli driving 
CRP production (Pepys and Hirschfield 2003). CRP responses can be observed in a num-
ber of different disease processes: infections, allergic complications of infection, inflam-
matory disease, necrosis, trauma or malignancies. Also physiological processes influence 
circulating CRP concentrations. We have recently described the CRP changes in non-
professional marathon runners (Bekos, Zimmermann et al. 2016). It is therefore very clear 
that CRP plasma (or serum) concentrations can only be interpreted in the clinical context 
(Pepys and Hirschfield 2003). CRP is a well established clinical marker indicating in-
flammation, infection and tissue damage  (Pepys and Hirschfield 2003). 
More recent is the interest in CRP serum concentrations in patients with cancer. 
Studies on the prognostic value of circulating CRP in patients with solid organ malignan-
cies are accumulating (exemplary): gall bladder cancer (Saqib, Pathak et al. 2018), ma-
lignant pleural mesothelioma (Ghanim, Hoda et al. 2012), pancreatic cancer (Szkandera, 
Stotz et al. 2014), non-small cell lung cancer  (O'Dowd, McRae et al. 2010), hepatocel-
lular carcinoma (Nishikawa, Arimoto et al. 2013), nasopharyngeal carcinoma (Fang, Xu 





Fibrinogen is a heterodimeric molecule consisting of two parts with different polypeptide 
chains: Aα, Bβ, γ linked by disulphide bridges. It is produced by hepatocytes in response 
to proinflammatory cytokines (e.g. IL-6) and a major plasma component (Tennent, 
Brennan et al. 2007). One of its main functions pertains to coagulation. Thrombin cleaves 
Aα and Bβ to release fibrinopeptides A and B which polymerize to an insoluble fibrin 
clot. The endogenous fibrinolytic system can subsequently form fibrin degradation prod-
ucts (Lowe, Rumley et al. 2004). Further fibrinogen was shown to bind activated platelet 
glycoprotein receptor IIb/IIIa on the surface of activated platelets leading to platelet ag-
gregation (Lowe, Rumley et al. 2004). Plasma fibrinogen concentrations are influenced 
by physiological, pathological and life style factors: inceased fibrinogen (genetic factors, 
age, gender, season, pregnancy and contraception, menopause, smoking, exercise, acute 
phase reactions) vs. decreased fibrinogen (A-, hypo- or Dysfibrinogenaemina; liver dis-
ease, disseminated intravascular coagulation, thrombolytic therapy, hemodilution), re-
spectively (Mackie, Kitchen et al. 2003, Lowe, Rumley et al. 2004).  
A prognostic role for plasma fibrinogen concentrations in thoracic: breast (Wen, Yang et 
al. 2015), non-small cell lung (Jiang, Li et al. 2014) and esophageal cancer (Wakatsuki, 
Matsumoto et al. 2017); and extra-thoracic malignancies: gall bladder (Shu, Weng et al. 
2014), gastric (Lee, Lee et al. 2012), colorectal (Yamashita, Kitayama et al. 2009) and 
hepatocellular cancer (Huang, Jiang et al. 2018) is emerging (selected publications). 
2.11.3 NLR and PLR: the role of neutrophils, lymphocytes 
and platelets in cancer 
If a malignancy progresses protumorigenic inflammatory and immune mechanisms are 
stronger than their antitumorigenic counterparts. Cells of the innate and adaptive immune 
system have roles in different stages of tumor development: tumor initiation, promotion, 
invasion and metastasis (Grivennikov, Greten et al. 2010). Indices formed from platelets 
and immune/inflammatory cells such as neutrophils and lymphocytes are currently inves-
tigated for their prognostic potential regarding outcomes of cancer treatment (Ong, 
Garcea et al. 2008, Wu, Shi et al. 2014, Zhang, Jiang et al. 2015, Yodying, Matsuda et al. 
2016, Hsueh, Tao et al. 2017, Pedrazzani, Mantovani et al. 2017, Turri-Zanoni, Salzano 




Neutrophil subpopulations are important in cancer development. Their granule proteins 
released following neutrophil activation are involved in cancer progression. Also, neutro-
phils can promote tumor cell proliferation, angiogenesis, matrix remodelling or interfere 
with T cell dependent anti-tumor immunity in part by direct interation of neutrophils with 
tumor cells (Mollinedo 2019). 
Lymphocytes can exert tumor-suppressive or tumor-promoting effects (Grivennikov, 
Greten et al. 2010). Their effects are related to the type of lymphocyte: B cells or T cells 
and their respective subtypes. Lymphocytes exert their effects  via direct cytotoxicity or 
the production of cytokines (Grivennikov, Greten et al. 2010).  
Platelets have a role in the tumor microenvironment. Evidence for tumor induced platelet 
activation nurturing cancer progression by mechanisms of tumor cell induced platelet ag-
gregation were described (Gasic, Gasic et al. 1968). The release of ADP and thrombin 
causes platelet activaton involved in tumor metastasis (Asghar, Parvaiz et al. 2019). Fur-
ther platelets can reduce NKG2D expression in natural killer cells and form an platelet-
fibrin-tumor aggregate for immune evasion (Erpenbeck and Schon 2010, Asghar, Parvaiz 
et al. 2019). Platelets were also found to mediate drug resistance of cancer cells (Huong, 





Patients with the rare disease TETs are being treated worldwide in multiple institutions 
in small numbers only. High quality evidence from randomized controlled trials regarding 
surgical or multimodal therapies is lacking. The overall aim of this PhD thesis was to 
increase scientific knowledge on surgically treated patients with TETs with particular 
emphasis on prognostic information.  
3.1 Prognostic factors and multi-modal manage-
ment of TETs treated in a single European thoracic 
surgery center 
The aim of this study was to determine quality of care at the institutional thoracic surgery 
Division by assessing survival and recurrence outcomes and confirmation of the value of 
(well) accepted pathological prognostic information. This study set the ground for further 
studies more experimental studies on prognostic predictors. 
The primary objective of the study was to determine prognostic factors in patients with 
TETs undergoing resection and multimodal treatment in a single central European tho-
racic surgery unit. The secondary objective was to perform a thorough analysis and doc-
umentation of all aspects of surgical treatment, such as surgical approach, extent of re-
section, and the treatment of recurrences.   
3.2 Prognostic factors for TETs with pleural involve-
ment: an ESTS Thymic Working Group Project 
The status of surgical resection with or without ChT and/or RT for primary or recurrent 
TETs with pleural involvement is not sufficiently defined yet, due to limitations in the 
available data. There are no large-scale studies dedicated to describing the value of pari-
etal pleurectomy and/or EPP in patients with pleural and/or pericardial involvement or 
dissemination of TETs. That is why we were interested in retrospectively collecting data 
about survival, recurrence or progression and multimodal therapy in patients treated with 
parietal pleurectomy or EPP. Because the number of thoracic surgery cases for thymic 




institutions the value of surgical treatment of this disease at primary presentation and its 
recurrences has not been explored sufficiently. 
The aim of this multi-institutional effort was to gain scientific data in the rare disease of 
TETs with pleural involvement with a special emphasis on prognostic information. 
The primary objective of the study was to determine prognostic factors in patients with 
TETs with pleural involvement undergoing resection and multimodal therapy at multiple 
institutions participating in ESTS Thymic Working Group projects. The secondary ob-
jective was to perform a thorough analysis and documentation of all aspects of surgical 
treatment, such as surgical approach, extent of resection, and the treatment of recurrences. 
3.3 CRP as a prognostic marker for TETs 
The study aim was to test for pretreatment and follow-up biomarkers valuable in estimat-
ing diagnosis, prognosis and surveillance of patients with TETs. 
The primary objective of the study was to evaluate CRP serum concentrations as pretreat-
ment prognostic factors in patients with TETs. The secondary objective was to investigate 
CRP as a biomarker for oncological follow-up of patients with TETs. As a tertiary ob-
jective this study also attempted to elucidate the possible source of CRP in patients with 
TETs. 
3.4 Fibrinogen, NLR, and PLR as prognostic markers 
for TETs 
The study aim was to develop pretreatment and follow-up biomarkers in patients with 
TETs. 
The primary objective of the study was to determine the value of fibrinogen serum con-
centrations, NLR and PLR as pretreatment prognostic factors in patients with TETs. The 
secondary objective was to evaluate fibrinogen serum concentrations, NLR and PLR as 





4.1 Ethical considerations 
Ethical approval for all the studies described in this PhD thesis was obtained from the 
institutional ethics committee of the Medical University Vienna. Written informed con-
sent was obtained from all patients and volunteers who donated blood for study purposes. 
All serum samples were drawn at the Division of Thoracic Surgery, Division of Surgery, 
Medical University Vienna. Tumor tissues were retrieved from the Clinical Institute of 
Pathology, Medical University Vienna. All experiments were performed in accordance 
with the approved ethical guidelines. All data of patients and volunteers enrolled in this 
study were handled carefully and will not be passed to third persons. Every participant 
was given a unique code to ensure protection of personal data and sample evaluation. In 
addition, for the multi-institutional study “Surgical therapy of thymic tumours with pleu-
ral involvement: an ESTS Thymic Working Group Project” each participating institution 
obtained ethical approval from its ethics committee. 
4.2 Research facility 
All the laboratory work was performed at the Department of Surgery (ARGE Moser and 
ARGE Ankersmit, FOLAB - Surgical research facilities), Medical University Vienna. 
Infrastructure needed for the project like ELISA Reader, laminar flow, fridge, freezer, 
centrifuge, etc. was already present. 
4.3 Prognostic factors and multi-modal management of 
TETs: a single center experience 
4.3.1 Study design 
The study was designed as a retrospective observational study (case series study) in order 
to describe the disease characteristics and outcome of patients treated for the orphan dis-
ease TETs at the Division of Thoracic Surgery, Department of Surgery, Medical Univer-




4.3.2 Patients, diagnostic workup and treatment decisions, tumor 
staging and histology 
Patients undergoing thoracic surgery for TETs during the indicated time period at the 
thoracic surgery division were included in the study. Only one patient had primary sur-
gery for a TET before this period. A total of 79 patients were identified. We excluded 
seven patients undergoing treatment for recurrences or progressions referred from other 
institutions because of lack of stage information at diagnosis and primary treatment at the 
referring institutions. Disease and treatment-specific documentation as well as follow-up 
information was complete for 72 patients. 
The preoperative diagnostic workup of patients with suspected TETs consisted of blood 
testing, ECG, pulmonary function tests, neurological examination (to diagnose of exclude 
paraneoplastic disease, especially MG), CT scan of the chest and in the more recent past 
PET or PET CT in more advanced cases.  
In patients with anterior mediastinal tumors where a clinical suspicion of lymphoma was 
raised preoperative biopsies were obtained to avoid futile surgery for lymphoma. Pre-
operative histological confirmation via core-needle biopsy was also obtained in cases 
where induction chemo- and/or radiotherapy were favored to primary resection of a sus-
pected TET. Anterior mediastinal tumor biopsies were performed without traversing the 
pleura in order to avoid pleural spread of the suspected TET. Decisions on multimodal 
therapy were decided on by a dedicated panel of experts in thoracic surgery, oncology, 
radiotherapy, neurology and pathology. 
The Masaoka-Koga staging system was used as the standard to document tumor stage 
(see tumor staging 2.7). Pathologists employed the WHO histological classification sys-
tem (combined TETs are specifically analyzed in this report; see histology 2.3) and re-
currences were reported as recommended by ITMIG (see 2.8). Only patients after R0 
resection were included in the analysis of freedom-from recurrence. Time-to-progression 
was analyzed in patients after R1 or R2 resection with partial remission or stable disease 
after chemotherapy and/or radiotherapy. 
Survival of patients undergoing surgery with different outcomes (remission, recurrence, 
progression) and different treatment modalities: surgery with or without chemo- and/or 




tumor classification, preoperative biopsies, multimodal therapy, MG, age and gender was 
explored. 
 
4.3.3 Statistical analyses 
SPSS software (version 17; SPSS Inc., Illinois, United States) was employed for statisti-
cal analysis. GraphPad Prism6 (GraphPad Software Inc., California, USA) was 
used for graphical display of all box plots and Kaplan-Meier curves. The probability of 
making a type I error was set at an α value of 0.05. The null hypothesis was rejected if 
the p-value was less than α . Two-tailed p-values were employed. Statistical 
independence of demographic data was computed with the Pearson χ2 test. Kaplan-Meier 
survival analysis and log-rank test were employed to assess outcome measures such as 
OS, CSS and FFR for TETs. Recurrences and outcome measures were reported as rec-
ommended by ITMIG (see Chapter 2.10.1). 
 
4.4 Surgical therapy of thymic tumours with pleural in-
volvement: an ESTS Thymic Working Group Project 
4.4.1 Study design 
The order the achieve the objectives an international multi-institutional study under the 
patronage of the ESTS Thymic Working Group was initiated to collect a large enough 
patients cohort for outcome analysis. On behalf of the ESTS Thymic Working Group 
emails were sent to ESTS members to recruit thoracic surgery centers for participation on 
the project. Participating institutions received a detailed standardized questionnaire to ob-
tain standardized retrospective data sets. Ten European and two Canadian institutions 
provided retrospective data from 152 patients of thymomas and TCs with pleural disease 







Table 9: Participating institutions and patient characteristics. Basic demographics and clinical parameters 
of all reported cases of each collaborating ESTS Thoracic Surgery Center. f:m ratio, female:male ratio; 
CHU Marseille, Centre Hospitalier Universitaire Marseille; UZ Leuven, Universitair Ziekenhuis 
Leuven; MUW, Medical University Vienna;  
Basic demographic and clinical parameters n % 
Total number of cases 152 100 
f:m ratio 76:76 50:50 
Age in years mean/median [range] 50.4 / 51.0 [22-75] 
Continent Country Institution   
Europe 125 82 
France, Centre chirurgical Marie Lannelongue, Paris  38 25 
France, CHU Marseille 18 12 
Belgium, UZ Leuven 17 11 
Austria, MUW Vienna 16 11 
Great Britain, Guy's & St Thomas' Hospital, London 13 9 
Switzerland, Universitätsspital Zürich 9 6 
Italy, University of Torino 6 4 
Spain, Madrid HU Puerta de Hierro Majadahonda 4 3 
Spain, Unviersitario de Salamanca 2 1.5 
Great Britain, Papworth Hospital, Cambridge 2 1.5 
North America Canada   
Canada, Toronto 23 15 
Canada, Montreal 4 3 
Decade of diagnosis 152 100 
1977-1990 2 1.3 
1991-2000 12 7.9 
2001-2010 86 56.6 
2011-2014 52 34.2 
Pleural Surgery for TETs 152 100 
Surgery for pleural recurrence 45 29.6 
Primary pleural surgery  107 70.4 
Diagnosis 152 100 
Thymoma 135 88.8 
Thymic Carcinoma 17 11.2 
 
Data stem from specialized thoracic surgery centers routinely performing surgery on pa-
tients with TETs. The study period was defined by the reported patients: thoracic surgery 
cases from February 1977 and November 2014. Only few cases were reported before 
January 2001 (90% of patients had surgery between January 1, 2001 and November 30, 
2014). Survival analysis was performed on all 152 patients. Analysis of FFR was done 
on 115 patients with complete surgical resection (R0;  See  
Figure 16). The calculated median follow-up time of the entire patient cohort was 52 







Figure 16: Flow chart illustrating the assignment of patients to different endpoints. 
Two types of clinical scenarios were analysed and described in this effort:  
Patients with pleural disease of TETs at primary diagnosis (70.4%) as well as patients 
with pleural disease who had previous surgery for a TET (without involvement of the 








Figure 17: Primary pleural surgery and surgery for recurrent pleural disease. Schematic to clarify terms for 
recurrent disease: In scenario 1 patients underwent radical surgery for TETs without pleural involvement. 
TETs with pleural disease occurred at recurrence. In scenario 2 patients TETs involving the pleural at first 
presentation were treated by surgery.  
4.4.2 Statistical analyses 
Statistical analysis of data was computed using SPSS software (version 21; IBM SPSS 
Inc., IL, USA). All plots were created using GraphPad Prism6 (GraphPad Software Inc., 
California, USA). The probability of making a type I error was set at an α value of 0.05. 
The null hypothesis was rejected if the p-value was less than α. Two-tailed p-values were 
employed. Kaplan-Meier product-limit method was used to estimate outcome measures 
for TETs (OS, CSS, DFS and FFR). The log-rank test was used to test differences between 
survival rates. Univariate and multivariate Cox proportional hazard models were used to 
evaluate prognostic factors for the same outcomes: OS, CSS and FFR. The following 
potential predictors were tested: age (continuous), sex, MG, thymoma vs. TC, resections 
status (complete vs. incomplete), type of surgery for pleural disease (EPP, TP or LP), 
primary pleural surgery vs. pleural surgery for recurrence, preoperative therapy, and post-
operative therapy. Recurrences and outcome measures were reported as recommended by 
ITMIG (Huang, Detterbeck et al. 2011). OS was calculated as the primary outcome from 
the date of surgery (first pleural surgery, see  
Figure 16 and Figure 17) to the date of death of any cause (censored observations: patients 




as death from TET (censored observations: unrelated deaths and unknown cause of death) 
(Huang, Detterbeck et al. 2011). DFS was analyzed from the date of first pleural surgery 
to the date of recurrence or death from any cause (Ruffini, Detterbeck et al. 2014). FFR 
was calculated only in patients after complete surgical resection (R0) from the date of 
first pleural surgery to the date of recurrence in patients with full information on recur-
rence status (Ruffini, Detterbeck et al. 2014). Log-rank test was used to compare Kaplan–
Meier curves. The differences at 1, 3, 5 and 10 years were reported descriptively. 
4.5 Evaluation of CRP as a prognostic marker for TETs 
4.5.1 Study cohort 
At the institutional division of thoracic surgery of the Medical University Vienna 149 
patients who underwent surgical tumor resection between June 1990 and May 2015 were 
included. Nintety percent of patients were treated  from 2002 to2015 with a follow-up 
time ranging from 1–249 months (median 35 months). Eighty patients (53.7%) received 
multimodal treatment, consisting of surgery with neoadjuvant or adjuvant Cht and/or RT. 
Sixty-nine patients (46.3%) underwent solely surgical tumor resection. Recurrences after 
treatment were observed in 27 patients (18.1%). The recurrence types were as follows: 
local 7 patients ( 25.9%), regional 10 patients (37.0%) and distant 10 patients 
(37.0%). 
Routine follow-up 
Preoperative staging was performed by Chest CT scans and in cases of advanced tumor 
stage with PET-CT. All patients were followed-up with periodic chest CT-scans. A neu-
rologist was consulted  for the diagnosis or exclusion of MG in all cases.  
Measurement of CRP serum concentrations  
CRP serum concentrations were measured usinga latex-enhanced immunoturbidimetric 
assay (Roche, Mannheim, Germany). Measurements were performed at the institutional 
department of laboratory medicine of the Medical University of Vienna. 
In-/Exclusion criteria of the study 
Since CRP serum concentrations are possibly altered by Cht or surgery there had to be at 
least 4 weeks between last applications of ChT or surgery and the blood draw to generate 




pneumonia (4 patients), urinary tract infections (3 patients), COPD exacerbation and 
acute cardiac insufficiency. 
Preoperative CRP serum concentrations were missing in 14 out of 149 patients with 
TETs. One-hundred and twenty-eight patients with TETs were available for CRP analy-
sis.  
The collection of postoperative follow-up serum samples started in 2012. For 68 patients 
pre- and postoperative CRP serum concentrations with median follow-up of 14.8 months 
[range 0.13–105.6 months] were available (recurrences: 16; no recurrence: 52 patients). 
CRP serum concentrations of 64 healthy volunteers matched for sex- and age served as 
controls.  
4.5.2 Tumor samples, Immunohistochemical analysis 
We performed immunohistochemical staining according to standard protocols [16, 24]. 
Sections 3-μm thick (formalin-fixed and paraffin embedded tissue) specimens of TETs 
were deparaffinized. Citrate buffer (pH 6.0, Target Retrieval Solution, DAKO, Glostrup, 
Denmark) was employed for antigen retrieva  by boiling slides at 600 watt 3 × 5 min in a 
microwave oven. Endogenous peroxidase was quenched with 0.3% hydrogen peroxide. 
Sections were incubated with monoclonal rabbit anti-human CRP antibody (Clone Y284, 
Abcam, Cambridge, UK) for 1 h at room temperature and goat anti-rabbit antibody was 
used as secondary antibody (Vectastatin ABC kit, Vector Laboratories, Burlingame, 
USA). Immunoreactivity was amplified by using biotin-avidin peroxidase conjugates 
(Vectastatin ABC kit, Vector Laboratories, Burlingame, USA) and 3,3´-diaminobenzi-
dine was used as chromogen (DAB Peroxidase substrate kit, Vector Laboratories, Burlin-
game USA). Sections were counterstained with hematoxylin. Liver specimens were used 
as positive control. The monoclonal rabbit anti-human CRP antibody (Clone Y284, 
Abcam, Cambridge, UK) was previously used to analyze CRP expression in hepatocellu-
lar carcinomas [30, 47]. 
4.5.3 Statistical analyses 
Statistical analysis of data was performed by using SPSS software (version 21; IBM SPSS 
Inc., IL, USA). All plots were created using GraphPad Prism6 (GraphPad Software Inc., 
California, USA). Non-normal distributed variables were analyzed with Whitney U-Test 




normal distribution were compard with unpaired student’s t test and one-way ANOVA. 
Post hoc comparisons were computed with Tukey’s-B. Nominal variables were compard 
with Chi-square test. Pearson`s correlation coefficient ( r) computed to describe linear 
relationships between two numerical variables. Kaplan-Meier survival analysis and Log-
rank test were used to analyze OS, CSS and FFR. Cox regression analysis was employed 
to assess prognostic factors and calculate Hazard Ratios (HR) with 95% confidence in-
tervals (CI). Univariable and multivariable analysis of gender (male vs. female), age (con-
tinuous), MG (pos. vs. neg.), tumor histology (TC vs. Thymoma), completeness of resec-
tion (R0 vs. R1+2), Masaoka-Koga stage (I+II vs. III–IV), tumor size (continuous) and 
pretreatment CRP (low vs. high) for OS, CSS and FFR was performed. The median 0.22 
mg/dL was used to dichotomize pretreatment CRP values into high and low CRP groups 
for survival analysis. The institutional laboratory cut-off value of 0.5 mg/dL was used to 
test the diagnostic accuracy (sensitivity, specificity, Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV)) of CRP. The probability of making a type I error was 
set at an α value of 0.05. The null hypothesis was rejected if the p-value was less than α. 
Two-tailed p-values were employed. We followed the definitions of recurrence and out-
come as recommended by ITMIG and ESTS Thymic Working Group (see 2.10).  
4.6 Evaluation of fibrinogen, NLR, and PLR as prog-
nostic markers for TETs 
4.6.1 Study cohort 
We analyzed 122 patients (57.4% females) with TETs who underwent surgical tumor 
resection at the Division of Thoracic Surgery, Medical University of Vienna between 
September 1999 and June 2015. Eighty percent of patients were treated within the past 
10 years. Mean patient age was 56.5±16.1 years. There were 92 thymomas (75.4%) and 
30 TCs (24.6%). Fifty-four percent of patients underwent multimodal treatment regimens 
combining surgery with radiotherapy and/or chemotherapy. A complete tumor resection 
(R0) was achieved in 89.3% of cases. Preoperative staging included chest CT scans, and 
in advanced cases PET-CT scans. Surgical resection alone was performed in 45.9% of 
cases. Fifty-four percent of patients underwent multimodal therapy including surgery. 




up was routinely performed according to  recommendations of the European Society of 
Thoracic Surgery (ESTS) (Ruffini, Detterbeck et al. 2014): chest CT scans every 3 to 6 
months for the first three years after surgery, followed by annual CT scans. 
 
4.6.2 Blood work and immunohistochemistry on tumor tissue 
Cell counts and fibrinogen measurements 
Fibrinogen, platelet count and the following cell counts: white blood cells, neutrophils 
and lymphocytes were measured at the institutional department of laboratory medicine 
during routine preoperative work-up one day before surgery to exclude coagulation dis-
orders or presence of acute infection. Measurements were repeated 3 to 7 days postoper-
atively, and at 6 to 12 months after the initial therapy. Fibrinogen plasma concentrations  
were evaluated using the Clauss method (Clauss 1957). Pre- and postoperative as well as 
further follow-up fibrinogen plasma concentrations were available from 112, 98, and 27 
patients, respectively. Longitudinal NLR values were available in 101, 95, and 36 pa-
tients, respectively. Longitudinal PLR values were available for 96, 95, and 36 patients, 
respectively. Fibrinogen, NLR, and PLR measurements from 51 healthy sex- (24 male, 
27 female) and age-matched (54.6 ± 1.4 years) volunteers served as controls. 
 
Immunohistochemistry 
Immunohistochemistry was performed using the automated Ventana Benchmark® plat-
form (Ventana Medical Systems, Tuscon, AZ, USA). The following antibodies were 
used: monoclonal mouse anti-human CD45 (LCA; 2B11& PD7/26; Cell Marque, Cali-
fornia, USA,) polyclonal rabbit anti-human Fibrinogen/FITC (Dako, Denmark). For 
CD45 staining (identify cells of the hematopoietic lineage), heat pre-treatment was per-
formed for 56 min in Ultra cell conditioner Nr 1 buffer (Ultra CC1; pH 6). For Fibrinogen 
staining, Protease 1 was applied for 8 min. Samples were incubated with primary anti-
bodies for 30 min, and then development was performed using the Ultraview Universal 
Detection DAB-kit. 
4.6.3 Statistical analyses 
Statistical analysis of data was performed by using SPSS software (version 22; IBM SPSS 




California, USA). Non-normal distributed variables were analyzed with Whitney U-Test 
and Kruskal-Wallis rank test. Means of two or more than two independent groups with 
normal distribution were compard with unpaired student’s t test and one-way ANOVA. 
The Chi-square test was employed to assess associations between nominal variables. Sur-
vival analyses were performed using Kaplan-Meier analysis and the Log-rank test. We 
followed the definitions of recurrence and outcome ( CSS and FFR) as recommended by 
ITMIG and ESTS Thymic Working Group (see 2.10).  
The receiver operating characteristic (ROC) curve was plotted to calculate the Youden 
Index (optimal cut-off value) for fibrinogen of 452.5 mg/dL to dichotomize into high and 
low fibrinogen groups of patients. An empiric cut-off value of 4.0 was employed to dif-
ferentiate between high and low NLR cohorts [32, 62]; and a median PLR of 136.5 di-
chotomized into high and low PLR cohorts.  
We evaluated the prognostic significance of histology (TC vs. Thymoma), Masaoka-
Koga tumor stage (I–II vs. III– IV), Fibrinogen (high vs. low), NLR (high vs. low), and 
PLR (high vs. low) on CSS and FF by univariable and multivariable Cox regression anal-
yses.  
Binary logistic regression was employed to evaluate the predictive values of fibrinogen, 
NLR, and PLR for detection of tumor recurrence within follow-up. R2 values are indi-





5.1 Prognostic factors and multi-modal management of 
TETs: a single center experience 
5.1.1 Survival is dependent upon tumor stage and resection status 
but not histology 
Seventy-two patients undergoing 84 surgeries (including surgery for recurrences) were 
included in the study. There were 44 females and 28 males. The mean patient age at sur-
gery was 58.2 [age range: 22 to 86] years. None of the patients died during thoracic sur-
gery or 30-days thereafter (no perioperative mortality). The median follow-up time cal-
culated from OS data (see Figure 18A) was 47.2 months. OS and CSS data from the entire 
patient cohort are listed for comparison in Table 10 (See Figure 18B). 
 
Figure 18: Overall and Cause-specific Survival in patients with TETs. OS is displayed by Kaplan–Meier 
curve with 95% confidence intervals (A). An overlay of OS and CSS (B), survival according to Masaoka–
Koga stage (C), survival and residual tumor status (D) are shown. A comparison of survival of patients in 





Table 10: OS and CSS of the entire patient cohort 
Survival 90% 80% 70% 
OS [months] 41.9 72.4 106.6 
CSS [months] 66.1 86.8  
 
Tumor stage 
There was decreased OS survival with more advanced disease as categorized with 
Masaoka-Koga stage (log rank test: p=0.017, Figure 18C). Stage presentation was as fol-
lows: stage I (29.2%), stage II (43.1%), stage III (13.9%), and stage IV (13.9%) (Table 
11). In stage I 90% of patients were alive at 116.6 months (end of follow-up period). In 
stage II OS was 90% at 41.9 months and 60% at 106.6 months. In stage III 80% survival 
was 72.4 months and 60% survival was 86.6 months. The worst survival was observed in 
stage IV with 90% at 14.5 months and 50% at 66.12 months. 
Residual tumor status 
Residual tumor classification was a predictor of survival after resection of TETs. OS was 
significantly worse following incomplete resection (R1+R2: 90% survival at 6.9 months, 
80% survival at 14.5 months, and 60% survival at 29.1 months; R0: 90% survival at 72.4 
months; Figure 18D; log-rank test: p<0.001).  
Histology 
WHO histological subtypes A, AB, B1, B2, B3 and TC did not display differences in 
survival (log rank test: p=0.136). Formation of subgroups such as group1 (A, AB, B1) 
and group 2 (B2, B3, TC) did not reveal a significant survival benefit (p=0.151). The 
distribution of WHO histological types was: A (19.4%), AB (5.6%), B1 (6.9%), B2 
(22.2%), B3 (12.5%), TC (19.4%), combined (12.5%), and micronodular thymomas 
(1.4%). The majority of A and AB thymomas were in stages I (61.1%) and II (22.2%) 
and only sporadically in higher stages: one case of type AB thymoma in stage III (infil-
tration of the lung and pericardium) and two cases of type A in stage IVb (lymphogenous 
metastases). B2 components were present in all combined thymomas (66.7% type 








Table 11: Masaoka-Koga stage and WHO histology  
 
 
5.1.2 Worse survival in advanced cases: recurrences, pro-
gressions, and multimodal therapy 
Recurrences and Progressions 
Survival was significantly better in patients without recurrences or progressions (log-rank 
test: Figure 18E; p<0.001).  
Freedom-from-recurrence  
Eighty-nine percent (64 out of 72) patients had an R0 resection. Around 90% of patients 
after complete resection were free from a recurrence at 28.5 months (median follow-up 
time 48.2 months; Figure 19A). 
Time-to-progression 
Eight patients (after R1 or R2 resection) showed the following time to progression: 90% 
of patients free from progression at 4.2 months, 70% at 6.3 months, 60% at 6.8 months, 








Figure 19: Outcome measures for recurrence and progression. Freedom-from recurrence (A) and time-to-
progression (B) in patients undergoing thoracic surgery for TETs (including patients with multimodality 
treatments). Kaplan–Meier curves with 95% confidence intervals are displayed.  
 
During the oncological follow-up 60 patients (83.3%) were free from recurrence or progression. There were 
seven (6.9%) recurrences and five (9.7%) progressions (two were referrals from other institutions). There 
were 10.9% recurrences after R0 resection compared to 50% recurrences (3 patients) after R1 resection and 
all patients following R2 resection (2 patients) developing a progression. Recurrence according to stage 
was as follows: I (1 patient, 4.8%),  II (3 patients, 9.7%), III (2 patients, 20%), and IV (1 patient, 10%). All 
five stage IV patients with incomplete resections (R1+R2) developed progressions (50% of stage IV pa-
tients). Stage and recurrence or progression were significantly correlated (Pearson χ2 test: p=0.001). Re-
currences in different WHO types were as follows: A (1 patient, 7.1%), AB (0%), B1 (0%), B2 (1 patient, 
6.3%), and micronodular thymoma (0%), B3 (2 patients, 22.2%), thymic carcinoma (2 patients, 14.3%), 
and combined thymomas (1 patient, 11.1%). One patient with WHO type B3 (11.1%), three patients with 
TC ( 21.4%), and one patient with combined thymoma (11.1%) experienced progressions. One patient had 

















Table 12: Local, regional and distant recurrences. 
 
 
One out of 34 patients treated with surgery alone had a recurrence. In comparison, of 38 
patients undergoing multimodal therapy, 11 patients experienced recurrences or progres-






Table 13: Treatment of recurrences  
 
 
Multimodal treatment of TETs: Surgery alone vs. Surgery plus Chemo- and/or Ra-
diotherapy  
The frequency of surgery plus multimodal therapy was significantly higher in patients in 
higher Masaoka–Koga stages (see also Figure 20). The survival analysis of surgical ther-
apy alone revealed 80% survival at the end of the follow-up period. Patients that were 
treated with surgery in conjunction with chemo and/or radiotherapy displayed the follow-
ing survival: 90% at 29.1 months, 80% at 45.9 months, 70% at 72.4 months, and 60% at 




Thirty-nine patients (54.2%) underwent combined treatment protocols consisting of sur-
gery with chemotherapy and/or radiotherapy in a neoadjuvant or adjuvant setting while 
33 patients (45.8%) were treated with surgery alone. Multimodal therapy regimens were 




Figure 20: Treatment modality with respect to pathological stage. Patients with stage I TETs were primarily 
treated by thoracic surgery alone. The use of multimodal therapy regimens increased with higher Masaoka-
Koga stage and was the case in 100% of stage IV patients. 
The decision for neoadjuvant treatment was influenced by tumor size (e.g. two patients 
in stage I with tumors >10 cm, and radiological suspicion of invasion of adjacent struc-
tures in CT and MRI scans (final pathological stage yI after neoadjuvant therapy and 
resection was reported). Twelve patients with TC (85.7%) received multimodal therapy. 
Completeness of resection was the most important determinant for decision making on 
adjuvant therapy. Surgical treatment alone was only performed in patients after histolog-
ically confirmed R0 resections. After R0 resections, 31 patients (51.6%) received adju-
vant therapy. All patients with R1 (6 patients) and R2 resections (2 patients) on final 
pathologic analysis received adjuvant therapy. 
Radiotherapy 
Thirty-seven radiotherapies were administered to 31 (out of 72) patients (radiotherapy for 
recurrence or progression included). Two patients were excluded from this analysis (no 
information on radiation dose and selective internal radiotherapy for liver metastases). 
The mean cumulative dose for neoadjuvant treatment was 51.2 Gray (6 patients) and the 




cumulative radiotherapy doses for progressive (3 patients) and recurrent disease (3 pa-
tients) were 40.7 and 42.7 Gray, respectively. None of the six patients treated with neo-
adjuvant radiotherapy received it in an adjuvant or recurrence/ progression setting. 
Chemotherapy 
Twenty (out of 72) patients underwent chemotherapy: neoadjuvant (10 patients; 1 patient 
received additional chemotherapy for a recurrence), adjuvant (5 patients), for recurrence 
only (1 patient), for progression only (2 patients). Cytotoxic platinum-based therapy was 
employed in 13 (65%) patients. In two patients (10%), protocols without platinum were 
used (chemotherapy protocols was not available in 5 patients).   
5.1.3 The role of biopsies and surgery 
Survival analysis of age (log-rank test: p=0.779), sex (p=0.646), or the use of preoperative 
biopsies (p=0.833) revealed no statistically significant differences. 
Biopsy 
Preoperative biopsies in to confirm the histological entity of the tumor were obtained in 
31 patients (43.1%). The biopsies were performed on tumors in different pathological 
stages: I (10 patients, 47.6%), II (8 patients, 25.8%), III (7 patients, 70%), and IV (6 
patients, 60%). The risk for recurrences was not increased in patients undergoing pre-
operative biopsies of thymomas/TC (log-rank test: p=0.571). There were five (16.1%) 
recurrences in patients who had a biopsy and two (4.9%) recurrences in patients without 
preoperative biopsies. Postoperative progressions occurred in two patients (6.5%) who 
had a biopsy and in three (7.3%) without a biopsy. 
Surgical approach 
The frequency of surgical incisions applied was: sternotomy (45.8%), thoracotomy 
(23.6%), or hemiclamshell incision (13.9%)  
 
 
Table 14. In a stage IV patient with excellent response after neoadjuvant treatment a cervical incision was 
used to remove lymphogenous metastases in the neck. In patients undergoing neoadjuvant treatments for 
primary tumor with suspicion of invasiveness and 12 cm and 10 cm in their greatest dimensions hemiclam-











Table 14: Surgical approach to TETs in different stages 
 
 
Extent of resection 
Data on the extent of resection were analyzed for 83 resections (missing data for one 
surgery). Pericardial resections were performed in 26 cases (31.3%). The following pul-
monary resections were performed in 22 (26.5%) cases: 17 segmental resections, three 
lobectomies, one pneumonectomy, and one lobectomy plus a segmental resection, one 
extrapleural pneumonectomy and 11 (13.3%) partial pleural resections. Unilateral resec-
tions of the phrenic nerve, recurrent laryngeal nerve and vagal nerve en bloc with the 
directly infiltrating tumors were performed in 16, 1 and 2 cases. Resection of diaphragm 
(3 cases, 3.6%), ribs (2 cases, 2.4%), clavicle (1 case, 1.2%), chest wall (1 case, 1.2%), 
and part of the liver (1 case, 1.2%) was performed. Vascular resection with reconstruction 
was done in 11 cases (13.3%): anonymous vein (7 cases), superior vena cava (7 cases), 
and subclavian artery (1 case). Tangential adventitial resections of the aortic arch and 
pulmonary trunk were feasible in two cases. 
5.1.4 Myasthenia Gravis was not a prognostic factor 
The presence or absence of MG was not a relevant factor for survival analysis (log-rank 
test: p=0.235). The diagnosis of MG was present at the time of surgery in 21.4% of male 
and 29.6% of female patients. MG was associated with 55% of B3, 37.5% of B2, 33.3% 
of combined and 21.4% of type A thymomas (only one case in B1 and TC), respectively. 
Thymoma patients with MG were encountered in 38.7% of stage II, 20% of stage III, 19% 




5.2 Surgical therapy of TETs with pleural involvement: 
an ESTS Thymic Working Group Project 
Patients undergoing primary surgery for pleural disease of TETs had a mean age of 47.3 
years and 54.6 years for patients with surgery for their first recurrent disease to the pleura. 
Forty patients (26.3%) had surgery for a TET before the first surgery of pleural disease. 
5.2.1 TC and incomplete resection predict worse survival  
OS, CSS, DFS and FFR of the entire patient cohort at 1, 3, 5 and 10 years is depicted in 
 
Table 15 and with Kaplan-Meier curves in Figure 21, respectively. 
 
Table 15: OS, CSS, DFS and FFR of the entire patient cohort 
Survival 1 year 3 year 5 year 10 year 
OS % (n=152) 96.4 91.0 87.2 62.7 
CSS % (n=152) 97.8 94.9 92.3 79.7 
DFS % (n=152) 84.3 60.9 44.9 15.2 
FFR % (n=115) 83.1 57.9 43.0 22.2 
 
 
Figure 21: Survival analysis: entire patient cohort. Overall survival (A), disease-free survival (B), cause-






Perioperative mortality (30 days) after pleural surgery for TETs: one patient with TC 
suffered from pneumonia and acute respiratory distress syndrome after EPP and another 
patient with TC undergoing total pleurectomy died due to acute pulmonary embolism and 
prolonged air leak. Mortality between 30 and 90 days postoperatively: One patient with 
B2 thymoma undergoing EPP had a non-tumor related cause of death. Mortality between 
90 days and 1 year: A TC patient who underwent EPP died related to progression of 
metastatic disease at 8 months. Another patient with B2 thymoma died 10 months after 
EPP from pneumonia resulting in acute respiratory distress syndrome. 
Survival analysis for prognostic factors 
Analysis at 3, 5 and 10 years revealed statistically significant better OS in patients under-
going surgery for pleural recurrence compared to primary pleural surgery (p=0.028, 
p=0.023, p=0.027, respectively). As expected the analysis at 3, 5 and 10 years revealed 
better OS in patients after complete compared to incomplete resections: R0 vs. R1/R2 
(p=0.032, p=0.003, p=0.001, respectively). The type of surgery: EPP vs. TP vs. LP was 
not associated with differences in FFR, but with differences in OS [1-year: p=0.010], DFS 
[3-year: p=0.021 and 5-year: p=0.037] and CSS [1-year: p=0.012 and 3-year: p=0.041]. 
TC compared to thymoma was associated with worse survival for all computed outcomes: 
OS, DFS, CSS and FFR at 1, 3, 5 and 10 years. There was a statistically significant sur-
vival advantage for patients with MG (10-year OS: p=0.010; the 5 and 10-year CSS: 






Figure 22: Survival analysis for prognostic factors. Comparison of primary pleural surgery and pleural 
surgery for recurrence OS (A), FFR (B), type of surgery: EPP vs TP vs LP: OS (C), FFR (D), thymoma vs 
TC: OS (E), FFR (F), and completeness of resection: OS (G), FFR (H). 
 
Pericardial resection (non-EPP patients), was associated with significantly worse survival 




yes (n=52) vs. no (n=52): 98.0% vs. 100.0% (p=0.322), 93.3% vs. 100.0% (p=0.082), 
86.7% vs. 97.0% (p=0.082), and 55.1% vs. 87.2% (p=0.010), respectively. 
5.2.2 The prognosis of patients with pleural disease is multi-
factorial: resection status, histology, primary or recur-
rent disease, type of pleural surgery and necessity of 
multimodal treatment  
Univariable analysis 
MG was associated with better OS [HR 0.234; p=0.019]. Incomplete resection, histology (TC vs. 
thymomas), primary pleural surgery vs. surgery for pleural recurrence, type of pleural surgery 











Table 16). The number of resected nodules (n = 122) when dichotomized with a cut-off value of 
4 (median number of resected nodules) revealed no statistically significant differences. 
Multivariable analysis 
TC histology in comparison with thymomas showed worse OS [HR 6.506; p=0.002], CSS [HR 
13.144; p=0.001] and FFR [HR 2.442; p=0.027], respectively. Incomplete resection was a pre-
dictor of worse OS [HR 6.696; p=0.003] and male sex predicted worse FFR [HR 1.800; p=0.033]. 
Analysis of patients after complete resection (R0) eliminates the potential strong bias of incom-
plete resection on other potential predictors: There was worse OS for male sex [HR 3.176; 
p=0.025], TC [HR 3.988; p=0.013], primary pleural surgery compared to surgery for pleural re-














Table 16). Analysis all patients with [pseudo-]neo- and [pseudo-]adjuvant therapy combined 













Table 16: Univariate and Multivariate Analysis of Predictors for OS, CSS and FFR.  
1Analysis of primary pleural surgery vs. pleural surgery for recurrence (both study cohorts are operated for 
pleural disease of TETs for the first time). 2Patients received (pseudo-) neoadjuvant therapy, including ChT 
± RT. 3Patients received (pseudo-) adjuvant therapy, including ChT ± RT. 4FFR was analyzed only for 
patients after complete resection (R0). 
 Univariate Model  Multivariate Model 
   95% CI    95% CI 
 HR p Lo-
wer 
Upper  HR p Lo-
wer 
Upper 
Overall survival          
Sex (Male) 1.508 0.322 0.669 3.397  2.438 0.092 0.865 6.871 
Age (continuous) 1.026 0.161 0.990 1.063  1.017 0.395 0.978 1.058 
Myasthenia Gravis (Yes) 0.234 0.019 0.069 0.790  0.551 0.459 0.114 2.666 
TC vs. Thymoma 6.315 0.000 2.652 15.040  6.506 0.002 1.956 21.646 
Incomplete resection 3.916 0.001 1.727 8.882  6.696 0.003 1.944 23.060 
Pleural Surgery 
Primary pleural Surgery vs. 


















Type of pleural Surgery 

















Preoperative Therapy (Yes)2 3.086 0.013 1.271 7.463  1.495 0.427 0.554 4.032 
Postoperative Therapy (Yes)3 2.558 0.030 1.093 5.988  1.733 0.293 0.622 4.831 
Cause-specific survival          
Sex (Male) 1.740 0.331 0.569 5.325  3.206 0.128 0.715 14.372 
Age (continuous) 1.041 0.108 0.991 1.093  1.039 0.197 0.980 1.101 




TC vs. Thymoma 12.129 0.000 3.867 38.044  13.144 0.001 2.726 63.370 
Incomplete resection 2.004 0.255 0.606 6.628  2.053 0.387 0.402 10.487 
Pleural Surgery 
Primary pleural Surgery vs. 


















Type of pleural Surgery 

















Preoperative Therapy (Yes)2 2.179 0.180 0.697 6.803  1.072 0.914 0.593 3.788 
Postoperative Therapy (Yes)3 2.066 0.203 0.675 6.329  1.020 0.976 0.288 3.613 
Freedom-from-fecurrence4          
Sex (Male) 1.541 0.096 0.926 2.566  1.800 0.033 1.050 3.086 
Age (continuous) 1.007 0.523 0.985 1.031  1.009 0.504 0.983 1.036 
Myasthenia Gravis (Yes) 0.623 0.090 0.361 1.077  0.661 0.208 0.346 1.260 
TC vs. Thymoma 2.748 0.006 1.330 5.676  2.442 0.027 1.106 5.388 
Pleural Surgery 
Primary pleural Surgery vs. 





















Type of pleural Surgery 

















Preoperative Therapy (Yes)2 0.852 0.542 0.508 1.427  0.577 0.068 0.319 1.042 
Postoperative Therapy (Yes)3 0.750 0.270 0.450 1.250  0.849 0.578 0.476 1.513 
 
 
5.2.3 Clinical data and treatment specifics for TETs with 
pleural involvement 
Clinical data 
Initial symptoms such as cough, muscle weakness, dyspnea or pain were reported in 
51.3% of patients. A preoperative biopsy was performed in 68.4%. MG was reported in 
47 patients (30.9%); other autoimmune diseases in 7.2% of patients (Isaac’s syndrome, 
paraneoplastic encephalopathy, systemic lupus erythematosus, rheumatoid arthritis, 
Good’s syndrome, pure red cell aplasia 3, Hashimoto’s thyroiditis 2, not specified 1). A 
previous extrathymic malignancy was present in 8.6% of patients (breast cancer 3, lym-
phoma 2, NSCLC 2, liposarcoma, melanoma, squamous cell carcinoma (SCC) of skin, 
thyroid cancer, parathyroid cancer, uterine tumor). There were 17 patients (11.2%) diag-
nosed with TC and 135 (88.8%) with thymoma. Pathological Masaoka–Koga Stages at 
their first surgery were reported as: I (3.4%), II (6.1%), III (20.5%), IVA (65.0%) and 
IVB (4.8%). The frequency of thymomas and TCs according to WHO histology was B2 
(33.6%), B3 (23.9%), B1 (13.0%), combined B2/B3 (11.6%), TC (10.3%), AB (4.1%), 
B1/B2 (2.0%), A (0.7%) and combined B3/TC (0.7%). 




The surgical approaches for the resection of TETs with pleural involvement were: thora-
cotomy 61 patients (40.4%), sternotomy 65 (43.0%) clamshell 6 (4.0%), hemi-clamshell 
16 (10.6%) and VATS 3 (2.0%). For primary pleural surgery (Scenario 2) EPP, TP and 
LP were performed in 32 cases (29.9%), 13 cases (12.1%, including 1 case of pleurec-
tomy/decortication [P/D]) and 62 cases (57.9%), respectively. In cases of pleural surgery 
for recurrence (Scenario 1, first pleural surgery) EPP, TP and LP were carried out in 8 
patients (18.2%) and 10 patients (22.7%, including 3 patients with P/D) and 26 patients 
(59.1%), respectively.  
Residual tumor status following primary pleural surgery was R0 (76 patients, 71%), R1 
(16 patients, 15%) and R2 (15 patients, 14%). The residual tumor status after recurrent 
pleural surgery was reported as: R0 (40 patients, 90.9%), R1 (1 patient,  2.3%) and R2 (2 
patietns, 4.5%), respectively (missing information: 2 patients). 
Treatment of the diaphragm in patients with TETs and pleural involvement 
Fifty-two non-EPP patients with diagphragmatic metastasis underwent either diaphrag-
matic resections: 34 cases: 6 complete and 28 partial resections (missing information on 
resection extent in 2 cases), or  16 pleurectomies of the diaphragm without resection of 
the diaphragm. Patients after oncologic phrenic nerve resection (with resultant diaphrag-
matic paralysis underwent diaphragmatic plication (5 patients). 
Multimodal therapy 
Of the 152 study patients in 67 patients (62.2%) received neoadjuvant therapy and 15 
patients (33.3%) pseudo-neoadjuvant therapy before surgery for recurrence. Sixty-eight 
patients (63.6%) underwent adjuvant treatments and 10 patients (22.2%) pseudo-adjuvant 
therapy after surgery for recurrence, respectively. PAC ChT (planned protocol: cisplatin 
50 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2) was administered 
as  neo- and pseudo-neoadjuvant treatment in 45 patients of the 76 (59.2%) patients of 
patients undergoing ChT. Administration of radiotherapy was reported as neoadjuvant (8 
patients), pseudo-neoadjuvant (1 patient), adjuvant (63 patients) or pseudoadjuvant (5 pa-
tients) treatment. Radiation doses ranged from 20–56 Gray (median 45Gray) for neoad-
juvant therapy and 24–60 Gray (median 50 Gray) for adjuvant therapy. 
Recurrence after surgery with or without chemo- and radiotherapy for pleural dis-




Fifty-five months was the median time from primary TET surgery without involvement 
of the pleura to surgery for recurrence of disease to the pleura (first pleural surgery, Sce-
nario 1). The median time to recurrence after the first pleural surgery was 46 months. In 
59 patients (51.3%) a recurrence was diagnosed after R0 resection with or without ChT 
and/or RT for TETs with pleural involvement. The types of recurrence were as follows: 
local 15 of 59 (25.4%), regional 30 of 59 (50.8%), distant 9 of 59 (15.3%) or local and 
regional 5 of 59 (8.5%), respectively. 
Surgical complications 
There were reports on 103 patients experiencing complications (44 patients) 
or documented follow-up without complications (59 patients).  
 
 





Table 17: Complications after pleural Surgery for TETs. EPP, Extrapleural pneumonectomy; TP, Total 
pleurectomy; LP, Local pleurectomy; n, number; ARDS, acute respiratory distress syndrome; MODS, multi 
organ dysfunction syndrome 
 Type of pleural Surgery 






Complications n % n % n % 
Chylothorax 0 0 1 5 1 1.9 
Hemothorax/postoperative bleeding 2 6.7 1 5 5 9.4 
Bronchial stump fistulation  2 6.7 0 0 0 0 
Prolonged air leak 0 0 1 5 3 5.7 
Pulmonary Embolism 1 3.3 0 0 0 0 
Wound Infection 2 6.7 0 0 1 1.9 
Horner’s Syndrome 0 0 1 5 1 1.9 
Empyema 2 6.7 0 0 1 1.9 
Pneumonia, Atelectasis, ARDS 3 10 5 15 3 5.7 
Renal Failure 2 6.7 0 0 0 0 
Cardiac Event 3 10 1 5 0 0 
Septic Shock/MODS 1 3.3 0 0 0 0 
Thrombosis of reconstructed central veins 1 3.3 0 0 0 0 





5.3 CRP serum concentrations predict poor outcome 
and tumor recurrence in patients with TETs 
5.3.1 Survival analysis: Increased pretreatment CRP is a 
predictor of worse FFR 
Pathological Predictors of outcome 
The histopathological differentiation of  thymoma and TC revealed a significant sur-
vival advantage for patients with thymomas: OS: p=0.001, CSS: p<0.001 and FFR: 
p=0.002, respectively. Also, patients after complete resection of their TETs (R0) had a 
statistically signifcant better survival outcomes than incompletely resected patients 
(R1+R2): OS: p=0.003, CSS: p<0.001 and FFR: p=0.039, respectively. Masaoka-Koga 
tumor stages III and IV were associated with significantly worse CSS: p=0.008 and 
FFR: p=0.002, respectively.   
Ajuvant therapy and outcome 
In this patient cohort OS and CSS were not statistically different with or without adju-
vant therapy (p=0.424 and p=0.117; respectively). Median FFR was significantly worse 
in patients with adjuvant therapy (128.5 months; 95% CI 40.7–216.3 months) compared 
those without 160.7 months (95% CI 30.6–290.8 months; p=0.001). 
Pretreatment CRP and outcome 
Patients were dichotomized into low and high CRP (cut off value: median CRP serum 
concentration of 0.22 mg/dL). The survival outcomes OS: p=0.201 and CSS: p=0.501 
were not affected by increased pretreatment CRP, respectively ( See also Figure 23). 
Increased pretreatment CRP was a predictor of worse FFR 
Patients with TETs with high pretreatment CRP had significantly worse FFR compared 
to those with low CRP: FFR: 5-year:  high vs. low: 68.1% vs. 84.5% and 10- year: high 






Figure 23: Prognostic impact of CRP in TETs. Overall Survival, Cause Specific Survival and Freedom 
From Recurrence are shown (median CRP cut off value of 0.22 mg/dL) (A–C). P-value (Log-rank test). 
5.3.2 Pretreatment CRP is a prognostic factor for FFR 
Univariable analysis 
Presence of TC and incomplete resection were significant prognostic factors for worse 
OS, CSS and FFR, respectively. Advanced Masaoka-Koga tumors stage (III+IV) was 
also associated with shorter CSS and FFR. High pretreatment CRP serum concentra-
tions were prognostic with regard to FFR, while OS and CSS were not affected. See Ta-
ble 18 for numeric data. 
Multivariable analysis 
Presence of TC was statistically significant in predicting worse OS and CSS, respec-
tively, while there was no effect on FFR. Incomplete tumor resection (R1+2) was asso-
ciated with significantly worse CSS, while OS and FFR was not affected. CRP serum 




Presence of paraneoplastic MG, sex or tumor size did not effect OS, CSS or FFR at uni-
variable or multivariable analysis. Age as continuous variable significantly influenced 
OS, CSS and FFR, respectively. See Table 18 for numeric data. 
 
Table 18: Univariate and multivariate Cox regression analyses. HR, hazard ratio; p, p-value; CI, confidence 
interval; aCox-Regression; bmedian CRP (0.22mg/dL) was used for grouping patients into high and low 
CRP cohort. 
 Univariate Model  Multivariate Model 
   95% CI    95% CI 
 HR pa Lower Upper  HR pa Lower Upper 
Overall Survival          
Sex (Male) 1.134 0.822 0.380 3.377  0.627 0.536 0.143 2.749 
Age (continuous) 1.038 0.080 0.996 1.081  1.054 0.048 1.001 1.110 
MG (No) 6.361 0.077 0.820 49.340  0.358 0.360 0.040 3.234 
Histology (TC vs. Thymoma) 0.183 0.003 0.059 0.568  3.561 0.130 0.687 18.457 
Resection Status (R0 vs. R1-2) 0.194 0.008 0.058 0.653  2.308 0.347 0.403 13.211 
Tumor Stage (I+II vs. III-IV) 0.380 0.090 0.124 1.165  2.850 0.183 0.610 13.316 
CRP (low vs. high)b 0.477 0.240 0.139 1.639  2.601 0.188 0.627 10.799 
Cause Specific Survival          
Sex (Male) 1.732 0.472 0.387 7.742  1.151 0.925 0.061 21.627 
Age (continuous) 1.036 0.207 0.980 1.096  1.106 0.059 0.996 1.229 
MG (No) 2.843 0.334 0.342 23.651  8.559 0.291 0.160 458.83 
Histology (TC vs. Thymoma) 0.067 0.001 0.013 0.352  76.836 0.039 1.258 4694.5 
Resection Status (R0 vs. R1-2) 0.071 0.001 0.016 0.319  74.810 0.041 1.191 4700.1 
Tumor Stage (I+II vs. III-IV) 0.098 0.032 0.012 0.820  4.834 0.342 0.187 124.78 
CRP (low vs. high)b 0.561 0.530 0.093 3.397  1.331 0.862 0.054 33.048 
Freedom From Recurrence          
Sex (Male) 1.684 0.192 0.770 3.683  1.180 0.754 0.419 3.322 
Age (continuous) 0.964 0.008 0.938 0.991  0.927 0.129 0.937 1.008 
Myasthenia Gravis (No) 2.127 0.127 0.806 5.611  0.826 0.796 0.194 3.519 
Histology (TC vs. Thymoma) 0.275 0.003 0.116 0.651  2.428 0.189 0.646 9.125 
Resection Status (R0 vs. R1-2) 0.361 0.048 0.131 0.992  1.444 0.600 0.367 5.684 
Tumor Stage (I+II vs. III-IV) 0.307 0.004 0.136 0.689  1.600 0.433 0.494 5.177 
CRP (low vs. high)b 0.303 0.015 0.116 0.792  2.394 0.126 0.781 7.337 
5.3.3 CRP serum concentrations are increased in patients 
with TETs 
Increased CRP serum concentrations in patients with TETs  
Patients with TETs showed significantly higher pretreatment CRP serum concentrations 
compared to sex- and age-matched controls (TETs 1.03±0.3 mg/dL vs. controls 
0.16±0.03 mg/dL; p<0.001; Figure 24A). Thymomas 0.62±0.21 mg/dL, TCs 2.33±0.7 
mg/dL and TNETs 0.90±0.44 mg/dL compared to controls showed significantly differ-
ent CRP serum concentrations (one-way ANOVA: p<0.001; see Figure 24B for post 





Figure 24: CRP serum concentrations in TETs. Patients with TETs (n = 128) revealed higher CRP serum 
concentrations compared to controls (n = 64) (A). Thymomas (n=93), TCs (n=30) and TNETs (n=5) com-
pared to controls are shown (B). Highest CRP serum concentrations were found in metastatic TETs 
(Masaoka-Koga Stage IV; (C). In patients with high pretreatment CRP≥0.22 mg/dL, CRP serum concen-
trations decreased after complete tumor resection (n=52) (D), and increased significantly in cases of tumor 
recurrence (n=16) (E). 
 
CRP serum concentrations in different WHO histological subtypes 
One-way ANOVA revealed significantly different CRP serum concentrations between 
WHO subtypes (p=0.029), while further post hoc comparisons showed no differences. 
The highest CRP serum concentrations were detected in patients with TCs and the low-




We detected significantly higher CRP serum concentrations in patients with B3 thy-
momas compared to patients with A/AB/B1/B2 thymomas: 2.05±1.14 mg/dL vs. 
0.32±0.049 mg/dL; p=0.009).  
 
Table 19: Patient characteristics according to CRP serum concentrations.  
*recurrences were excluded; aindependent-samples t-test; bPearson’s χ2 test for independence; cone way 









Age (years)     
<56 63 1.37(0.24)±3.4(0.43)  
≥56 65 0.71(0.20)±1.5(0.20) 0.165a 
Sex    
Male 54 1.73(0.18)±3.9(0.58)  
Female 74 0.52(0.19)±0.9(0.11) 0.029b 
Tumor Subtype    
MNT 6 0.66(0.29)±0.74(0.30)  
A 15 0.46(0.19)±0.49(0.13)  
AB 19 0.18(0.15)±0.14(0.03)  
B1 11 0.38(0.18)±0.49(0.15)  
B2 26 0.25(0.10)±0.40(0.08)  
B3 16 2.05(0.34)±4.50(1.14)  
TC 30 2.33(0.72)±4.00(0.73)  
TNET 5 0.90(0.62)±0.98(0.44) 0.029c 
Tumor Stage     
I 27 0.57(0.20)±0.92(0.18)  
II 58 0.35(0.17)±0.56(0.07)  
III 13 2.01(0.60)±2.87(0.79)  
IV 30 2.33(0.55)±4.79(0.87) 0.003c 
local (I-III) 98 0.63(0.20)±1.32(0.13)  
metastases (IV) 30 2.33(0.55)±4.79(0.87) 0.038d 
non-invasive (I) 27 0.57(0.20)±0.92(0.18)  
invasive (II-IV) 101 1.15(0.22)±2.95(0.29) 0.317a  
early stages (I-II) 85 0.42(0.19)±0.70(0.08)  
advanced stages (III-IV) 43 2.24(0.60)±4.27(0.65) 0.002d 
Myasthenia Gravis     
Yes 34 0.91(0.13)±3.3(0.56)  
No 94 1.08(0.27)±2.4(0.25) 0.753a  
Tumor resection    
before surgery 52 0.57(0.20)±1.51(0.21)  
after surgery * 52 0.26(0.24)±0.22(0.03) 0.135e 
Follow up     
no recurrence 52 0.26(0.24)±0.22(0.03)  
recurrence 16 4.72(1.60)±6.44(1.61) 0.001d 
 
CRP serum concentrations in different Masaoka-Koga stages 
Different tumor stages displayed differing CRP serum concentrations (p=0.003; Figure 
24C; Table 19). The highest CRP serum concentrations were found in patients with me-
tastases (Stage IV disease) compared to local (stage I-III) TETs; p=0.038). For details 
and further comparisons see Table 19. 




Longitudinal analysis was performed in a subset of 68 patients. Pre- and postoperative 
CRP serum concentrations were available (median follow up of 14.8 months).  
In this subset of patients recurrences occurred in 16 patients (local: n=2, regional: n=4, 
distant: n=10), whereas 52 patients were without recurrence. In patients without tumor 
recurrence CRP serum concentrations decreased from 0.57±0.21 mg/dL preoperatively 
to 0.26±0.03 mg/dL postoperatively (p=0.135; Figure 24D).  
In case of tumor recurrence CRP serum concentrations increased significantly 
(4.72±1.61 mg/dL; p=0.001; Table 19; Figure 24E).  
Diagnostic accuracy of CRP to predict tumor recurrence 
We tested the accuracy of heightened CRP serum concentrations for prediction of tumor 
recurrence at a CRP cut off level of 0.5 mg/dL: sensitivity 62.5% (10 out of 16), speci-
ficity 92.4% (48 out of 52), PPV)71.4% (10 out of 14) and NPV 88.9% (48 out of 54), 
respectively. 
CRP is not expressed in TET tissue 
We found no CRP expression in 27 thymoma and 6 TC specimens by immunohisto-




5.4 Prognostic and diagnostic impact of fibrinogen, 
NLR, and PLR on TET outcome 
5.4.1 Survival and freedom from recurrence are associated 
with fibrinogen plasma concentrations, NLR and PLR 
Median follow-up time was 30.8 months. Fifteen fo the 122 patients (12.3%) suffered 
from a recurrence: 3 local, 4 regional, and 8 distant. High fibrinogen plasma concentra-
tions were associated with significantly worse FFR and CSS (Figure 25A and B).  
 
Figure 25: Kaplan–Meier survival in relation to fibrinogen plasma concentrations, NLR and PLR. Graphs 




(D) , and between PLR and FFR (E) and CSS (F). The cut-off values used to dichotomize patients into low 
and high subgroups were 452.5 mg/dL for Fibrinogen, 4.0 for NLR, and 136.5 for PLR. 
 
High NLRs were associated with significantly worse FFR and patients with high PLR 
with significantly worse CSS (Figure 25C-F). Patients with thymomas (but not TCs) with 
high pretreatment fibrinogen plasma concentrations had significantly worse CSS 
(p=0.013). Pretreatment NLR and PLR were not associated with statistical differences in 
CSS or FFR in patients with thymomas or TCs. 
 
5.4.2 Fibrinogen and NLR as predictors of survival and re-
currence 
FFR 
TC (HR 4.93) and high pretreatment NLR (HR 3.95) were significantly associated with 
worse FFR (univariable analysis). In multivariable analysis TC remained a statistically 
significant predictor of worse FFR (HR 8.55).  
CSS 
TC (HR 23.3), advanced tumor stage (HR 12.35) and high fibrinogen plasma concentra-
tions (HR 17.24) were associated with statistically significant worse CSS. See table Table 
20 for details of uni- and multivariable analysis.  
 
Table 20: Univariable and multivariable Cox regression analysis Presented data indicate the prognostic 
impact of tested factors. Patients were dichotomized into high and low subgroups using cut-off values 
of 452.5 mg/dL for Fibrinogen, 4.0 for NLR, and 136.5 for PLR. 
 Univariable Multivariable 
 HR  p-value  95% CI  HR  p-value  95% CI  
Freedom from recurrence 
TC vs. Thymoma 4.93  0.002  1.76–13.7  8.55  0.036  1.14–62.5  
Tumor Stage I–II vs. III–IV 2.60  0.066  0.94–7.14  0.68  0.673  0.12–4.02  
Fibrinogen (high vs. low)  2.86  0.053  0.99–8.26  1.40  0.601  0.40–4.95  
NLR (high vs. low)  3.95  0.014  1.32–11.7  3.14  0.145  0.67–14.7  
PLR (high vs. low)  2.00  0.259  0.60–6.67  0.44  0.350  0.08–2.46  
Cause specific survival  
TC vs. Thymoma  23.3  0.004  2.68–200.0  3.56  0.442  0.14–90.9  
Tumor Stage I-II vs. III-IV 12.35  0.022  1.43–111.1  3.10  0.459  0.16–62.5  
Fibrinogen (high vs. low)  17.24  0.012  1.87–166.7  9.09  0.149  0.45–166.7  
NLR (high vs. low)  62.5  0.265  0.04–100.0  0.61  0.677  0.06–6.10  







Preoperative Fibrinogen, NLR, and PLR in patients with TETs 
Patients with TETs showed significantly higher fibrinogen plasma concentrations com-
pared to healthy volunteers. Fibrinogen was significantly higher in patients with TCs 
compared to patients with thymomas. There were significantly higher NLR and PLR in 
patients with TETs compared to controls. Mean NLR and PLR values were significantly 
higher in patients with TCs than in patients with thymomas. See Table 21 for details. 
Thymoma subtypes according to the WHO classification 
Fibrinogen plasma concentrations were lowest in patients with MNT and AB thymomas. 
NLR and PLR values were lowest in patients with B1 thymomas and B2 thymomas (Table 
21). 
 
Table 21: Preoperative analysis of Fibrinogen, NLR, and PLR in patients with TETs. 
aunpaired Student’s t-test; bone-way ANOVA. 









n mean(median)±SD(SEM) p-value 
Age 
(years) 
         
<57 54 375.0(328.5)±121.3(16.5)  48 3.47(2.49)±2.79(0.40)  44 184.7(150.0)±107.2(16.2)  
≥57 58 404.3(370.5)±119.3(15.7) 0.201a 54 3.40(2.86)±2.42(0.33) 0.888a 51 175.7(142.0)±127.4(17.8) 0.715a 
Sex          
M 46 397.6(369.5)±139.5(20.6)  40 3.69(2.92)±2.41(0.38)  37 180.3(138.7)±99.2(16.3)  
F 66 384.9(353.0)±106.3(13.1) 0.586a 62 3.27(2.53)±2.71(0.34) 0.419a 58 179.5(150.0)±129.3(17.0) 0.976a 
WHO          
MNT 7 331.7(327.0)±90.8(34.3)  7 5.10(2.42)±3.81(1.44)  7 252.6(274.4)±142.3(53.8)  
A 14 405.2(385.5)±82.0(21.9)  14 3.32(3.04)±2.04(0.59)  12 198.8(167.8)±89.6(25.9)  
AB 16 341.5(315.5)±104.1(26.0)  16 2.93(2.97)±0.82(0.21)  14 140.7(126.3)±59.0(15.8)  
B1 10 361.9(358.5)±54.8(17.3)  10 2.19(0.18)±0.49(0.15)  10 110.7(83.8)±47.3(15.0)  
B2 22 364.7(351.5)±87.8(18.7)  22 2.70(2.47)±1.89(0.42)  18 124.5(108.6)±58.1(13.7)  
B3 15 363.5(334.0)±96.9(25.0)  15 2.71(2.53)±1.47(0.39)  13 152.4(139.5)±71.3(19.8)  
TC 28 469.4(473.0)±163.4(30.9) 0.003b 28 5.09(4.05)±3.84(0.82) 0.005b 21 268.2(230.0)±169.6(37.0) <0.001b 
Tumor 
Stage 
         
I 25 354.5(346.0)±65.1(13.0)  25 2.84(2.44)±1.69(0.36)  20 171.3(163.6)±74.4(16.7)  
II 53 364.1(352.0)±96.9(13.3)  53 3.09(2.69)±2.08(0.29)  48 145.3(129.4)±79.3(11.5)  
III 11 428.1(415.0)±126.5(38.1)  11 4.74(4.10)±3.88(1.29)  9 268.9(281.4)±145.5(48.5)  
IV 23 470.8(465.0)±169.3(35.3) 0.001b 23 4.45(3.22)±3.54(0.81) 0.061b 18 236.9(173.0)±179.7(42.4) 0.003b 
MG          
Yes 31 351.8(330.0)± 102.3(18.4)  31 3.11(2.40)±2.75(0.53)  26 161.5(133.5)±148.4(29.1)  
No 81 404.8(368.0)± 124.5(13.8) 0.037a  81 3.55(2.83)±2.54(0.29) 0.455a  69 186.7(158.8)±104.7(12.6) 0.356a  
Resection          
R0 101 388.7(359.0)±124.2(12.4)  101 3.51(2.65)±2.69(0.28)  86 183.5(142.2)±122.5(13.2)  









Yes 14 447.8(410.5)±158.4(42.3)  13 4.70(2.61)±3.87(1.07)  12 253.7(197.3)±202.6(58.5)  
No 98 381.9(358.0)±112.9(11.4) 0.056a 89 3.25(2.65)±2.32(0.25) 0.209a 83 169.1(135.2)±97.6(10.7) 0.181a 
 
Masaoka-koga tumor stage 
Advanced stage tumors (stage III–IV) had significantly higher Fibrinogen plasma con-
centrations, NLR and PLR compared to patients with early stage tumors (stage I–II; Table 
21). Fibrinogen plasma concentrations increased with tumor invasiveness: non-invasive 







Figure 26: Fibrinogen and absolute lymphocyte numbers according to Masaoka-Koga tumor stage. Fibrin-
ogen plasma concentrations gradually increased with invasiveness defined by stage (A). Peripheral blood 
absolute lymphocyte numbers gradually decreased with tumor stage (B). 
 
Paraneoplastic MG 
Twenty-six percent of 122 patients were diagnosed with MG. MG was prominent in pa-
tients with B2 thymomas (11 out of 24, 45.8%) and B3 thymomas (7 out of 17, 41.2%), 
respectively. Patients without MG had significantly higher preoperative fibrinogen 
plasma concentrations and tumor size. See Table 21 for details. There was no difference 
in fibrinogen plasma concentration comparing MG-negative and MG-positive thymomas 
(TCs excluded).  
Neutrophil, lymphocyte, and platelet blood counts in patients with TETs 
There was no statistically significant difference in absolute and relative neutrophil and 
lymphocyte counts as well as absolute platelet counts in relation to WHO histology or 
Masaoka-Koga stage (not shown). Absolute lymphocyte numbers in relation to TET lev-
els of invasiveness are depicted in Figure 26B: stage I: 1.98±0.80 G/L to stage IV (me-
tastasized) 1.43 ± 0.70 G/L (p = 0.822). We observed significantly higher absolute lym-
phocyte numbers in MG patients (2.09±0.7 G/L) compared to those without MG 





5.4.3 NLR and PLR as predictors of tumor recurrence during 
oncological follow-up 
Further we sought to investigate the value of fibrinogen, NLR and PLR as tumor markers 
within oncologic follow-up. We performed analysis of longitudinal measurements of pre-
operative, postoperative (3-7 days after surgery) and follow-up (6-12 months after sur-
gery) fibrinogen plasma concentration, NLR, and PLR.  
Preoperative values 
Patients with TETs had significantly higher mean preoperative fibrinogen plasma con-
centrations compared to healthy controls (390.2±11.4 mg/dL vs. 314.8±10.9 mg/dL; 
p<0.001), NLR (3.43±0.3 vs. 1.78±0.1; p=0.001), and PLR (179.8±12.1 vs. 133.4±7.1; 
p=0.001). 
Early postoperative period 
Fibrinogen plasma concentrations and NLR values 3-7 days after surgery were signifi-
cantly elevated in thymomas compared to their respective preoperative values (fibrino-
gen: 445.6±14.7 mg/dL vs. 364.7±9.8 mg/dL; p<0.001; NLR: 6.22±0.5 vs. 2.99±0.2; 
p<0.001); similarly in TCs (fibrinogen: 541.5±34.0 mg/dL vs. 469.4±30.9 mg/dL; 
p=0.006; NLR: 10.5±1.4 vs. 5.1±0.8; p=0.007). 
Oncological follow-up in thymoma and TC patients 
Six to twelve months following thymoma resection fibrinogen plasma concentrations and 
NLR were significantly reduced compared to early postoperative values (fibrinogen: 
356.5±25.2 mg/dL vs. 445.6±14.7 mg/dL; p=0.043; NLR: 4.37±0.5 vs. 6.22±0.5; 
p=0.004). In contrast, fibrinogen and NLR were not significantly reduced in TCs com-
paring the same time points (fibrinogen: 454.3±40.5 mg/dL vs. 541.5±34.0 mg/dL; p = 
0.635; NLR: 8.7±2.0 vs. 10.5±1.4; p=0.657).  
Follow-up (6-12 months) NLR values in patients with TCs  were significantly higher than 
preoperative values (8.7±2.0 vs. 5.1±0.8; p=0.028), while Fibrinogen plasma concentra-
tions did not significantly differ (454.3±40.5 mg/dL vs. 469.4±30.9 mg/dL; p=0.478). 
Follow-up fibrinogen plasma concentrations and NLR were similar to preoperative values 
in thymoma (fibrinogen: 356.5±25.2 mg/dL vs. 364.7±9.8 mg/dL; p=0.931; NLR: 
4.37±0.5 vs. 2.99±0.2; p=0.203) (Figure 27A, B, D, E).  
While postoperative PLR was significantly elevated in patients with thymomas (preop vs. 




TCs (207.8±29.3 vs. 168.2±37.0; p=0.546). During oncological follow up (6-12 months) 
the highest PLR for thymomas (212.5±24.8) and TCs (347.1±74.0) was detected (Figure 
27G and H). 
 
Higher NLR and PLR in patients with tumor recurrence 
Patients with tumor recurrence 6–12 months after surgical resection (with and without 
multimodal therapy) showed significantly higher NLR (p=0.001) and PLR (p=0.031) 
compared to those without recurrence (Figure 27F and I).  
The reasons for the NLR and PLR increases in patients with tumor recurrence was due to 
significantly lower absolute and relative lymphocyte numbers compared to patients with-
out (p=0.014 and p=0.027, respectively), while platelet and neutrophil counts displayed 
non-significant increases (p=0.492 and p=0.154, respectively). 
Serum concentrations of fibrinogen were not significantly altered in patients with recur-







Figure 27: Fibrinogen, NLR, and PLR before and aftger surgery and during oncologic follow up. Plots 
illustrate how surgical tumor resection and recurrence were related to Fibrinogen, NLR, and PLR in thy-
momas (A, D, G) and TCs (B, E, H), as well as the longitudinal courses of Fibrinogen, NLR, and PLR 
according to tumor recurrence among TETs (C, F, I). 
 
NLR and PLR as predictor of tumor recurrence during oncologic follow-up 
ROC analysis of NLR and PLR for predicting tumor recurrence is shown in Figure 28. 
NLR and PLR displayed high accuracy in predicting tumor recurrences: area under the 
curve (AUC) NLR: 0.819 and PLR: 0.787.  
Eighty percent sensitivity, 77% specificity, a PPV of 36.4, and a NPV of 96% were cal-
culated employing a NLR of 6.6 as a cut-off (Youden index 0.574) to predict tumor re-
currence. 
One-hundred percent sensitivity, 58.1% specificity, a PPV of 27.8%, and a NPV of 100% 




Binary logistic regression identified NLR as a significant factor predicting tumor recur-
rence (p = 0.043; R2: 0.378), but not PLR (p = 0.078; R2: 0.165) and Fibrinogen (p = 
0.341; R2: 0.054). 
There was no additive effect in predicting tumor recurrence when using combinations of: 
NLR and PLR (NLR: p=0.046; PLR: p=0.847; R2: 0.379), NLR and Fibrinogen (NLR: 
p=0.071; Fibrinogen: p=0.913; R2: 0.369), or PLR and Fibrinogen (PLR: p=0.165; Fi-
brinogen: p=0.892; R2: 0.192), respectively. 
 
 
Figure 28: Accuracy of NLR and PLR in predicting tumor recurrence in patients with TETs. Receiver 
operating characteristic (ROC) curves for the use of NLR (A) and PLR (B) to predict tumor recurrence 
during oncologic follow-up showed AUC values of 0.819 (p = 0.024) and 0.787 (p = 0.042), respectively. 
The dotted lines indicate the highest Youden Indices for NLR (Youden Index=0.574; sensitivity=0.800; 
specificity=0.226; cut-off at 6.6) and PLR (Youden Index=0.581; sensitivity=1.000; specificity=0.419; cut-
off at 202.5). 
 
Fibrinogen expression in TETs 
Immunohistochemistry for fibrinogen on  B2 and B3 thymomas revealed fibrinogen ex-
pression in endothelial cells and within thrombotic clots, but was absent from neoplastic 





Figure 29: Fibrinogen expression in B2/B3 thymoma. Staining of a B2/B3 thymoma (B3 part) with Hema-
toxylin-Eosin (A). Fibrinogen (B) and CD45 (C) expression. 100× magnification. Asterisks indicate neo-
plastic thymic epithelial cells. Arrows indicate cells of the hematopoietic lineage. Fibrinogen expression is 

















Thymomas and TCs are a rare tumor entities that display great subtype heterogeneity 
(Chau, Kim et al. 2010) and present in different clinical stages. Beyond that is the scat-
tered treatment of patients with TETs that is carried out in small numbers in many differ-
ent clinical departments without unified standards around the globe. The different prac-
tices for diagnosis, therapy, and follow-up of patients with TETs have resulted in poor 
understanding of their tumor biology and hindered the formulation of strong evidence-
based treatment guidelines. As a result, current patient care has a weak evidence base. 
Decisions on diagnosis, therapy and follow-up are influenced by the clinical team’s ex-
perience and reports from single institutions. 
6.1 Pathological prognostic biomarkers for TETs 
Relevance of prognositc factors at a single European thoracic surgery center 
The institutional study investigated the outcome of patients with TETs treated surgically 
with or without multimodal therapy over the past decade and thus formed the foundation 
for all further studies on prognostic factors at the department. Our single center study 
corroborated most of the widely accepted prognostic factors for the treatment of TETs, in 
particular completeness of resection (R0 vs. R1+2, log-rank test p<0.001) and Masaoka–
Koga stage log-rank test: p=0.017), but not WHO histological type (A, AB, B1, B2, B3, 
and TC, log-rank test: p=0.136) (Chen, Marx et al. 2002, Detterbeck and Parsons 2011, 
Venuta, Rendina et al. 2011). While eight (of 72) patients died from thymic neoplasms, 
three patients because of unrelated causes (two patients: coronary artery disease and one 
patient: gastric cancer) – corroborating the reporting standard of CSS in addition to OS 
for patients with TETs. Patients with advanced Masaoka-Koga stages not only displayed 
significantly worse prognosis regarding survival compared to patients in lower stages 
(log-rank test: p=0.017). This was accompanyied by a significantly higher frequency of 
recurrences and progressions in advanced stage tumors (Pearson χ2 test: p=0.001). Also, 
there was no significant survival difference comparing patients with MG to those without. 
The biologic absence of a fibrous capsule around the TET (desmoplastic reaction) as well 
as the disruption of loose areolar tissue surrounding it during postoperative handling and 




overestimation of the number of true R1 resections in the literature. New handling, pro-
cessing, and reporting guidelines will improve this misclassification (Huang, Detterbeck 
et al. 2011).  
There are several reports indicating that preoperative biopsies may be responsible for tu-
mor cell seeding (Nagasaka, Nakashima et al. 1993, Fujiwara, Matsumura et al. 2003, 
Kattach, Hasan et al. 2005, Choi, French et al. 2014). Our own data did not support a 
higher risk of recurrence or progression following TET biopsies. The institutional practice 
for performing preoperative biopsies are: (1) to identify the histological entity of the tu-
mor, (2) in patients with suspicion of lymphoma or (3) in patients with suspected invasive 
TETs before the administration of neoadjuvant therapy, without traversing the pleura. 
Prognositc factors for TETs with pleural involvement 
The  ESTS Thymic Working Group retrospective study contributes to a better understand-
ing of the role of surgery the setting of  TETs with pleural involvement. It reflects Euro-
pean and Canadian thoracic surgery practice patterns of institutions experienced in treat-
ing TETs with pleural and/or pericardial involvement. 
Multivariable analysis revealed that complete surgical resection (R0) and thymoma his-
tology (compared to TCs) are predictors of better OS. 
It is particularly remarkable that complete surgical resection was predictive of improved 
OS irrespective of the surgical method (EPP, TP or LP) used. It is clear that the underlying 
situation and spread of disease determine the indication for a specific surgical procedure 
(see also 2.9.4.2). Patients requiring EPP had more advanced TETs (involving not only 
pleura but also the lung) than those patients in which TP or LP was sufficient to achieve 
R0 resections. EPP for the most advanced cases of tumor spread yielded similar OS re-
sults comparable to far less invasive procedures (TP and LP) for more limted disease.  
Another key result of the study is that patients with thoracic surgery for recurrent disease 
to the pleura (first pleural surgery/Scenario 1) had better survival than those with surgery 
for primary pleural disease. A closer look at the patient cohorts reveals a bias in disease 
severity with resultant necessity for extended surgery in patients with primary pleural 
disease: (Scenario 2, primary tumor with pleural involvement): 29.9% EPPs, 15.0% TCs 




ment): 18.2% EPPs, 2.2% TCs and 6.8% incomplete resections). There is no fair compar-
ison of the two patient cohorts. Nevertheless the data underscore the excellent outcome 
of surgery for recurrent disease of TETs to the pleura (Lucchi, Davini et al. 2009).  
Other factors that may contribute are differences in the biology of TETs presenting with 
pleural involvement at first diagnosis (compared to those with first pleural involvement 
at recurrence) or effective follow-up after thymic surgery (tertiary prevention) succeeding 
in early diagnosis of recurrences after surgery (compared to those with pleural involve-
ment without prior thymic surgery (no primary prevention). 
Five-year OS of 87.2%.of the entire patient cohort in the current study compares favour-
ably to a JART study which reported on TET patients with pleural dissemination who 
underwent surgical resection: 118 patients in Masaoka Stage IVA and 18 in IVB with a 
5-year OS of 83.5% (Okuda, Yano et al. 2014). In studies of patients undergoing surgery 
for TETS with pleural dissemination with patients cohort sizes ranging from 5-21 patients 
5-year OS ranging from 43.1 to 92.3% was reported (Murakawa, Karasaki et al. 2015).  
In an ESTS database study on 229 TC patients including all tumor stages with 5- 
and 10-year OS rates of 0.61 and 0.37 and 5- and 10-year FFR rates of 0.60 and 0.43 
multivariate analysis revealed incomplete resection and Masaoka–Koga stage III–IV as 
negative predictors of OS (p<0.0001 and p=0.02), respectively (Ruffini, Detterbeck et al. 
2014). Our study revealed comparable OS for the 17 TC patients with pleural involve-
ment: 5- and 10-year OS: 56.0% and 0% (mortality: 6 deaths by the end of 10 years), 
respectively. 
The role adjuvant therapy in patients with pleural involvement is still unclear. In 
an ESTS cohort study on 2030 TET patients Masaoka–Koga stage III–IV, incomplete 
resection and non-thymoma histology were associated with more recurrences and worse 
survival while adjuvant therapy after complete resection was associated with improved 
survival (Ruffini, Detterbeck et al. 2014). In a JART study including 1320 patients 
Masaoka Stage IVA (118 patients) with ≤10 pleural nodules and macroscopic complete 
resection had better prognosis. The role of adjuvant therapy after R0 resection remained 
unclear (Kondo and Monden 2003). In another Japanese study on stage IVA patients that 
underwent R0 resection, no supportive data on the efficacy of ChT and/or RT were re-




The observed survival advantage of patients with MG may be just the result of 
more advanced disease in patients without MG: MG+ vs MG-: TCs 2.1% vs. 15.2%, in-
complete resections 17.4% vs. 25.0% and EPPs 10.6% vs. 33.7%, respectively. Better OS 
of MG patients was reported in a study on 797 thymoma patients (Filosso, Evangelista et 
al. 2015). In patients with TAMG of all stages, MG was associated with histology and 
stage, but only stage had a prognostic significance on OS and DFS (Ruffini, Filosso et al. 
2011). Closer follow-up of patients with MG may also be responsible for earlier diagnosis 
of TETs (Ruffini, Filosso et al. 2011). 
Since 90% of TET patients (64 of 71) underwent extended thymectomy at the time 
of primary pleural surgery and only six patients had thymomectomy only with with re-
currence rates of 49.0% and 50%,, no conclusions on the value of extended thymectomy 
compared to thymomectomy only at primary surgery for pleural disease of TETs can be 
drawn. 
Surgery of the diaphragm in patients with TETs with diaphragmatic metastases 
ranges from just pleurectomy of the diaphragm to partial or complete resection of the 
diaphragm. The extent of resection purely depends on the metastatic involvement of dia-
phragmatic pleura with our without involvement of diaphragmatic musculature. Dia-
phragmatic metastases were present simultaneously with metastases to other pleural sites 
what renders the separate analysis of different extents of diaphragmatic resection or just 
pleurectomy impossible. Diaphragmatic surgery may also be necessary for functional rea-
sons. After oncologic phrenic nerve resection  diaphragmatic plication is indicated in or-
der to avoid atelectasis of the lung. 
Limitations of the clinical studies 
The main limitations of both studies stem from their retrospective design and the long 
investigated study period that was necessary for gathering the large number of TET pa-
tients, particularly those with pleural involvement. During the large study period diag-
nostic and therapeutic algorithms may have changed due to technical advances (e.g. PET-
CT).  
Despite these limitations the relatively large number of patients analyzed in both studies 




Prospective studies on TETs  as well as TETs with pleural involvement are warranted. It 
is on ESTS, ITMIG or JART to prospectively collect data in large patient cohorts. We 
recommend close follow-up after surgery for TETs and TETs with pleural disease. 
6.2 Peripheral blood derived prognostic bi-
omarkers for TETs 
High pretreatment CRP serum concentrations in our study were associated with signifi-
cantly worse FFR, more aggressive tumors and advanced tumor stages. These findings 
are congruous with reports of increased CRP serum concentrations to be associated with 
worse outcome in other solid organ malignancies: breast cancer (CRP≥10 mg/dl, OS) 
(Villasenor, Flatt et al. 2014), gall bladder cancer (CRP≥10 mg/dl; OS) (Saqib, Pathak et 
al. 2018), malignant pleural mesothelioma (CRP≥1 mg/dL; OS) (Ghanim, Hoda et al. 
2012), pancreatic cancer (adenocarcinoma, CRP>4.5 mg/dL; CSS) (Szkandera, Stotz et 
al. 2014), non-small cell lung cancer (CRP>1 mg/dL; CSS) (O'Dowd, McRae et al. 2010), 
hepatocellular carcinoma (CRP>0.2 mg/dL; FFR) (Nishikawa, Arimoto et al. 2013) and 
nasopharyngeal carcinoma (Fang, Xu et al. 2017). In studies of nasopharyngeal cancer 
different cut-offs were applied for different patient cohorts, all indicating worse prognosis 
with elevated CRP (Fang, Xu et al. 2017): high sensitivity-CRP cut-offs ranging from 
1.96-3 in patients with non-metastatic (Tang, Hu et al. 2015) and primary nasopharyngeal 
carcinoma (Tang, Li et al. 2015) and CRP cut-offs ranging from 2.46-8 in patients with 
metastatic (Xia, Ye et al. 2013), newly identified (Xia, Zhang et al. 2013) and locore-
gional advanced nasopharyngeal carcinoma (Zeng, Wu et al. 2015). In a recent review 
elevated preoperative CRP serum concentrations were associated with higher mortality 
in adult patients with solid organ malignancies. The authors also concluded that CRP was 
useful to identify tumor recurrences (Shrotriya, Walsh et al. 2015). 
While other groups have shown that baseline as well as postoperative CRP se-
rum concentrations predict mortality in non-small cell lung cancer patients undergoing 
surgery (Pastorino, Morelli et al. 2017), our study focused on preoperative measure-
ments. We focused out studies on preoperative CRP serum concentrations in order to 
avoid the influence of different surgical methods, e.g. open surgery via thoracotomy or 
minimally-invasive robotic or VATS surgery, on the regularly occurring rises in postop-




stress on the patients that result in quantitatively different acute phase responses and 
CRP values (Asteriou, Lazopoulos et al. 2016).  
More evidence is accumulating the thymoma histology is of prognostic value (Ruffini, 
Detterbeck et al. 2014, Weis, Yao et al. 2015). In support of this are CRP serum concen-
trations differentiating thymoma types with better prognosis: A/AB/B1/B2  from those 
with poorer prognosis: B3 and TCs. 
TET recurrences can be observed in 10% to 30% of patients after complete resec-
tion of the primary TET – sometimes even decades after resection (Dai, Song et al. 
2015, Marulli, Margaritora et al. 2016). Surgical resection of tumor recurrence is a valid 
option leading to good long term OS (Sandri, Cusumano et al. 2014, Marulli, 
Margaritora et al. 2016). Reported 5- and 10-year OS after thoracic surgery for recur-
rence was 63 and 37%, respectively. Complete surgical resection was associated with a 
statistically significant better OS when compared to incomplete resection and non-surgi-
cal treatment (Marulli, Margaritora et al. 2016). In a multi-center study (3 centers, 81 
patients) 5- and 10-year OS after TET recurrence treatment (surgery in 75% of patients) 
were 73.6% and 48.3%, respectively. The study included local (mediastinum: 15 cases, 
pleura: 44 cases) as well as distant recurrences (15 cases). Five- and 10-year OS was 
better with 82.4% and 65.4% following a complete re-resection (R0) (Sandri, 
Cusumano et al. 2014). Therefore there is a real need for biomarkers useful for tertiary 
prevention after TET resection in order to detect tumor recurrences early when complete 
resection is possible. CRP serum concentrations might serve as a useful biomarker in 
this regard. Thus  future study of CRP serum concentrations for oncologic follow-up of 
patients after TET resection is warranted. CRP measurements can be readily included 
into follow-up routines. Due to the fact that CRP is not a specific marker for TETs or 
their recurrences clinicians have to evaluate other reasons for rises in circulating CRP 
(see also Chapter 2.11.1). Particularly infections as a source of serum CRP rises have to 
be ruled out before a high suspicion for recurrence can remain that  prompts further 
clinical and radiological examinations in the search for a possible tumor recurrence. 
With a PPV of 71.4% and NPV of 88.9% CRP could serve as an accurate biomarker for 
oncologic TET follow-up. CRP has several advantages over newer but more experi-
mental biomarkers (e.g. soluble RAGE, HMGB1(Moser, Janik et al. 2014), HSP27 and 




majority of hospitals worldwide and clinicians have already gained a vast experience 
with this biomarker.  
CRP expression in tumor tissue has been demonstrated several solid organ malig-
nancies, including hepatocellular carcinoma (Shin, Kim et al. 2015), esophageal squa-
mous cell carcinoma (Nakatsu, Motoyama et al. 2012) or renal cell cancer (Jabs, Busse 
et al. 2005) and intrahepatic cholangiocarcinoma (Yeh, Lei et al. 2017). In the case of 
TETs circulating CRP might not derive from the tumors as it was not detected by im-
munohistochemistry in our study. The source of circulating CRP remains elusive in our 
study. One might speculate that increased CRP serum concentrtaions in patients with 
TETs stem from cancer-related inflammation: interaction of immune cells and tumor cells 
leading to increased CRP production by hepatocytes via cytokine stimulation.  
Previously published work on HSPs (Janik, Schiefer et al. 2016) and RAGE axis 
molecules (Moser, Janik et al. 2014) from our group support cancer-related inflammation 
in TET patients. Proinflammatory HSPs and RAGE-ligands (Hofmann, Drury et al. 1999) 
were significantly elevated in patients with TETs and results were again pronounced in 
advanced tumor stages and more aggressive tumor subtypes (Moser, Janik et al. 2014, 
Janik, Schiefer et al. 2016). 
High fibrinogen plasma concentrations were identified in several types of cancer 
patients under going surgical tumor resection to be a statistically significant prognostic 
predictor of worse outcome and/or tumor progression (selected publications): breast can-
cer (≥283 mg/dl; OS) (Wen, Yang et al. 2015), gall bladder cancer (>402 mg/dL; OS) 
(Shu, Weng et al. 2014), gastric cancer (>407 mg/dl, OS) (Lee, Lee et al. 2012), colorectal 
cancer (>336 mg/dl; RFS) (Yamashita, Kitayama et al. 2009), non-small cell lung cancer 
(>400 mg/dl; DFS) (Jiang, Li et al. 2014) and esophageal cancer (>400 mg/dl; OS and 
RFS) (Wakatsuki, Matsumoto et al. 2017). A meta-analysis of studies investigating 
plasma fibrinogen concentrations in patients with hepatocellular carcinoma in China (7 
studies)  and Japan (1 study) with fibrinogen cut-off values ranging from 234.5-400 mg/dl 
concluded found worse prognosis (different outcomes were employed: OS, DFS, RFS) 
and advanced tumor progression in patients with higher circulating fibrinogen (Huang, 




Increasing fibrinogen plasma concentrations may indicate increasing tumor invasive-
ness/aggressivness. Our study revealed high pretreatment Fibrinogen plasma concentra-
tions to be statistically associated with advanced tumor stage, and worse survival out-
comes (FFR and CSS). Supporting this observation are pretreatment Fibrinogen plasma 
concentrations increasing from stage I to IV and the highest Fibrinogen plasma concen-
trations in TCs; and lowest in AB thymomas and MNT. These findings are in parallel to 
associations of increased pretreatment Fibrinogen plasma concentrations with advanced 
stage and worse outcome reported for patients with uterine leiomyosarcoma (Bekos, 
Grimm et al. 2017), nasopharyngeal carcinoma (He, Wang et al. 2017), malignant pleura 
mesothelioma (Ghanim, Hoda et al. 2014) and ovarian cancer (Hefler-Frischmuth, 
Lafleur et al. 2015) (selected publications). 
Recent research indicates different roles for fibrinogen in tumorigenesis and tumor me-
tastasis.  Endogenously synthesized fibrinogen enhances the growth of lung and prostate 
cancer cells through interaction with FGF-2 (Sahni, Simpson-Haidaris et al. 2008). Fi-
brinogen`s VE-cadherin binding domain induces endothelial barrier permeability and 
enhances transendothelial migration of malignant breast epithelial cells (Sahni, Arevalo 
et al. 2009). The number of spontaneous hematogenous and lymphatic metastasis wa 
significantly reduced in fibrinogen-deficient mice (Palumbo, Potter et al. 2002). 
Immunohistochemistry in tumor tissue of TETs revealed absent staining for fibrinogen 
in malignant thymic epithelial cells. The finding that fibrinogen plasma concentrations 
increased progressively with invasiveness together with absent expression in TET tissue 
let us hypothesize that increased fibrinogen plasma concentrations are the result of an 
acute phase response to TETs. 
Data in our study on NLR in TET patients are in line with a study on 79 Chinese TC 
patients undergoing complete resection. For TCs preoperative NLR>4.1 was significantly 
associated with larger tumor size, advanced Masaoka stages and reduced DFS and OS, 
but was not an independent predictor of survival in TC patients after complete resection 
(Yuan, Gao et al. 2016). In other solid organ malignancies, such as gall bladder cancer 
patients undergoing surgery high preoperative NLR (NLR cut-off range: 1.94-3.74) was 
a significanct predictor of worse survival at univariate (Ong, Garcea et al. 2008, Wu, Shi 
et al. 2014, Zhang, Jiang et al. 2015, Saqib, Pathak et al. 2018) and multivariate analysis 




were reported for cancers of the larynx (Hsueh, Tao et al. 2017), esophagus (Yodying, 
Matsuda et al. 2016), colon(Pedrazzani, Mantovani et al. 2017) and paranasal sinus 
(Turri-Zanoni, Salzano et al. 2017) (selected publications). In most studies the predictive 
power of NLR was reported to be superior to that of PLR. Also our data indicate this: 
NLR but not PLR was significantly associated with worse CSS.  
Recently the derived NLR (dNLR, calculated as neutrophil count divided by the subtrac-
tion of white blood cell count minus neutrophil count) was introduced in studies for the 
simple practical reason that only the white blood cell and neutrophil counts of patients 
were entered into clinical trial databases (Proctor, McMillan et al. 2012). Prognostic ob-
servations similar to NLR were reported for preoperative dNLR. DNLR was an independ-
ent prognostic predictor for time-to recurrence (TTR) and OS in patients with stage II and 
III colon cancer (Absenger, Szkandera et al. 2013). In patients with advanced gastric can-
cer undergoing preoperative ChT and followed by complete (R0) resection high baseline 
NLR was reported to be superior to d-NLR values in predicting postoperative outcomes 
(RFS and OS). Post-ChT NLR and d-NLR lost their usefulness due to the inhibition of 
bone marrow hematopoietic function (Jin, Sun et al. 2017). While in patients with HBV-
associated hepatocellular carcinoma treated by transarterial chemoembolization high 
NLR and dNLR predicted poor OS with similar prognostic power (Zhou, Liang et al. 
2016).  
Increased NLR or PLR are a result of increased neutrophils and platelets and/or decreased 
lymphocytes. So far numerous tumor-promoting and tumor-suppressing functions of het-
erogenous neutrophil populations, the different types of lymphocytes and platelets were 
described. The particular pathophysiological mechanisms involved in the prognostic role 
of NLR or PLR in various cancer is still to be elucidated. Our data revealed that absolute 
lymphocyte counts gradually decreased from non-invasive to metastasized TETs. The 
lowest lymphocyte counts were observed in patients with TCs. 
In our study, patients with TAMG had significantly higher absolute lymphocyte counts 
compared to TET patients without MG. This is in accordance to previous reports with 
higher numbers of naive helper and cytotoxic T cells in blood of TAMG patients 
(Buckley, Douek et al. 2001, Strobel, Helmreich et al. 2002). Significantly higher num-




(and in one MG negative thymoma patient who developed MG only 2 months after sur-
gery) compared to MG negative thymoma patients. These intratumoral findings were par-
alleled by significantly reduced percentages of naïve CD4+ T cells in peripheral blood of 
thymoma patients without MG (Strobel, Helmreich et al. 2002).  
We attribute the immediate increases of Fibrinogen plasma concentrations, NLR, and 
PLR in the early postoperative period directly to an acute phase response triggered by 
surgical stress (Volanakis 2001, Tennent, Brennan et al. 2007, Asteriou, Lazopoulos et 
al. 2016). TET patients experiencing tumor recurrences during oncological follow-up dis-
played 2.5-fold higher NLR and 1.8-fold higher PLR than in TET patients without recur-
rence. NLR and PLR were predictors of tumor recurrence with sensitivities of 80% and 
100%, and NPV of 96% and 100%, respectively. Higher NLR and PLR in TET patients 
suffering from tumor recurrences may be a consequence of cancer-related inflammation.  
CRP, fibrinogen, NLR and PLR are accurate, in most institutions readily estab-
lished and likely socio-economically feasible blood-derived biomarkers that could be of 
further help in the early diagnosis of TETs during oncologic follow-up. The predictive 
power of CRP regarding FFR (p=0.037; R2: 0.147) increased in combination with fibrin-
ogen (R2: 0.825), NLR (R2: 1.000), or PLR (R2: 0.726), respectively. 
In summary, from our data we believe that the observed increases of CRP, Fibrin-
ogen, NLR, and PLR are result from TET-related inflammation. This is in support of our 
findings on RAGE axis molecules and heat shock proteins involved in TET-related in-
flammation (Moser, Janik et al. 2014, Janik, Schiefer et al. 2016). Elevated CRP serum 
concentrations, fibrinogen plasma concentrations, NLR, and PLR were associated with 
worse outcome; and during oncologic followup, CRP, NLR and PLR were significantly 
increased in patients with tumor recurrence. 
Recommeded follow-up incorporating peripheral blood derived biomarkers 
Up to now clinical tertiary prevention programs lack adequate (bio-)markers. Currently 
the only recommended tools for oncologic follow-up of TET patients are CXRs and chest 
CT scans (Huang, Detterbeck et al. 2011). According to ESTS Thymic working group 
data the majority of institutions experienced with TET treatment performed chest CT 
scans 3- to 6-months after tumor resection for the first 3 years, followed by lifelong annual 
chest CT scans (Ruffini, Detterbeck et al. 2014). Similarly, ITMIG recommends a mini-




chest CT scans with annual CXRs until the 11th postoperative year; followed by annual 
CXRs alone. Additional chest CT imaging every 6 months for 3 years is suggested for 
resected advanced stage III or IVa thymoma, TCs, incomplete resection, or other “high-
risk” tumors (Huang, Detterbeck et al. 2011).  
We strongly believe that prospective tertiary prevention trials with biomarkers are war-
ranted, particularly in patients with increased CRP serum concentrations at diagnosis of 
a TET primary. Controlling CRP serum concentrations prospectively at regular intervals 
could probably lead to omission of chest CT scans. It certainly would not completely 
replace surveillance by CT. We propose the following protocol emedded into current rec-
ommendations of ESTS (Ruffini, Detterbeck et al. 2014) and ITMIG (Huang, Detterbeck 
et al. 2011) in order to evaluate the role of CRP serum concentrations for oncologic fol-
low-up: Chest CT scans every 6 months for the first 3 years followed by alternating chest 
CT scans with CXRs until the 11th postoperative year followed by annual CXRs only. At 
each check up CRP serum concentrations should be recorded. Further CRP serum con-
centrations should be further determined every 6 months. Increased CRP serum concen-
trations in the absence of other reasons for the CRP rise (e.g. infection, abscess) will 
prompt radiological imaging for detection/exclusion of a tumor recurrence. We believe 
that CRP measurements will increase the chance of detecting recurrences earlier particu-
larly when compared to CXRs (radiological sensitivity is low). Earlier detection of tumor 
recurrence may yield improved outcomes for patients. In an analogous manner follow-up 
programs incorporating plasma fibrinogen, NLR and PLR can be designed.  
Limitations of the studies investigating the prognostic value of CRP, Fibrinogen, 
NLR and PLR 
The studies on circulating CRP in serum, fibrinogen in plasma and NLR and PLR of TET 
patients is subject to limitations that apply to retrospective and single center experiences 
on orphan diseases, such as an inherent bias of selection and information. Nonetheless 
the studies also carry strength as they are the first to ascribe prognostic and diagnostic 
value to these peripheral blood parameters in TET patients. Also, the relatively large 
number of patients having this rare disease was sufficient for the identification of the 





The limitations can be overcome with future prospective multicenter studies to as-







The aim of this dissertation has been to identify pathological and clinical prognostic fac-
tors for patients with TETs. The following conclusions can be drawn from the results of 
the five scientific projects described in this thesis.  
 
1. We have identified the prognostic value of pathological Masaoka-Koga stage and 
completeness of resection  for patients with TETs at a single European thoracic 
surgery center. Multidisciplinary treatment decisions result in good patient care 
and treatment outcomes. 
 
2. From the international multicenter study we can deduct that in the rare instances 
of TETs with pleural involvement complete resection remains the mainstay of 
treatment. Thymoma histology (compared to TC) was predictive of improved sur-
vival. The surgical procedures EPP, TP and LP that were used to treat patients 
with different tumor distributions showed similar survival. It is important to note 
that the choice of the surgical procedure depends upon the extent of tumour dis-
tribution. EPP, TP and LP when performed as part of multimodal therapy seem to 
be efficient procedures for local control of disease yielding excellent results re-
garding OS, DFS, CSS and FFR. 
 
3. The measurement of pretreatmtent CRP serum concentrations might influence de-
cisions regarding the use of neoadjuvant therapy since it might be useful to indi-
cate highly aggressive TETs (TCs and metastatic TETs). High pretreatment CRP 
serum concentrations were associated with significantly worse 5- and 10-year 
FFR and a negative prognostic factor regarding FFR. CRP serum concentrations 
might also have a role in the oncological follow-up as they decreased after com-
plete resection and significantly increased in cases of tumor recurrences.  
 
4. Further evidence for the role of inflammation in the biological course of TETs can 
be seen in that high pretreatment Fibrinogen serum concentrations were signifi-
cantly associated with worse CSS and FFR, high NLR with worse FFR, and high 




concentrations, NLR, and PLR to be associated with higher Masaoka-Koga tumor 
stage and more aggressive tumor behavior such as seen in TCs. Next to its poten-
tial predictive and diagnostic role there might also be a value of high NLR and 
PLR in oncological follow-up of TETs as observed in high NLR and PLR of pa-
tients with tumor recurrence (compared to those without). 
 
The results of the thesis contribute to research on diagnosis, treatment and prognostication 
of patients with TETs in that previously described pathological prognostic factors have 
been confirmed in the setting of a single institutional experience and in the largest multi-
institutional effort of TETs with pleural involvement. The prognostic potential of inflam-
matory parameters used in daily clinical routine were identified as promising future diag-
nostic, therapeutic or predictive targets. 
In the era of evidence based medicine global efforts are warranted in this orphan 
disease to initate prospective studies with larger number of patients to obtain higher levels 







Objective: Thymic epithelial tumors (TETs) are a malignant orphan disease that is 
characterized by the frequent occurrence of recurrences. Pretreatment prognostic infor-
mation and biomarkers for oncological follow-up are not available. The aim of this thesis 
was to investigate the role of surgery in special situations such as pleural spread of TETs, 
the prognostic value of pathological characteristics and laboratory parameters of clinical 
routine: Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), 
Fibrinogen and C-reactive protein (CRP). 
Methods: Standardized datasets of patients undergoing thoracic surgery for TETs of all 
tumor stages at the Medical University Vienna as well as patients undergoing surgical 
therapy for TETs with pleural disease at ten European and two Canadian thoracic surgery 
institutions were analyzed. For the experimental part tumor tissues and serum samples of 
patients with TETs, benign thymic disease and healthy volunteers were collected.  
Results:  
Pathological predictors of outcome In patients with TETs of all stages completeness of 
resection and stage were significant pathological prognostic factors. Pleural involvement 
resulted from thymomas in 89% and thymic carcinomas (TCs) in 11.2%. Forty extrapleu-
ral pneumonectomies (EPPs), 23 total pleurectomies (TPs), and 88 local pleurectomies 
(LPs) were performed (completeness of resection in 76.8%). OS for the entire patient 
population at 1, 3, 5 and 10 years was 96.4%, 91.0%, 87.2% and 62.7%, respectively. 
There was no statistically significant difference regarding FFR and OS for patients with 
local or advanced disease undergoing EPP, TP or LP. TCs in comparison with thymomas 
had a negative impact on OS, CSS and FFR. Incomplete resections predicted worse OS. 
Pretreatment predictors of outcome Pretreatment CRP serum and Fibrinogen plasma 
concentrations, NLRs and PLRs were significantly elevated in patients with TETs, par-
ticularly TCs and advanced tumor stages. High pretreatment CRP, Fibrinogen, NLR and 
PLR were associated with worse outcomes. 
Biomarkers for follow-up  





Conclusions: The widely accepted pathological prognosticators stage and resection 
status were confirmed. Furthermore in TETs with pleural involvement complete resection 
remains the mainstay of treatment. EPP, TP and LP employed for different tumor distri-
butions yield excellent local control and survival outcomes. Peripheral blood-based in-
flammation markers: CRP, fibrinogen, NLR and PLR warrant future propective study to 







Célkitűzés: A thymus epitheliális daganatai (thymic epithelial tumors - 
TETs)  ritka malignus megbetegedések, amikre jellemző a gyakori kiújulás, 
a recidívák megjelenése. Jelenleg nem ismerünk megbízhatóan alkalmazható 
prognosztikai faktorokat és biomarkereket sem a kezelés előtt a túlélés meg-
becsülésére, sem az onkológiai követéshez. Ennek a disszertációnak a céljai 
között szerepelt a sebészi eltávolítás szerepének vizsgálata speciális esetek-
ben, mint a TET pleurális terjedésének jelenlétében; a patológiai jellemzők, 
valamint a klinikai gyakorlatban használt laboratóriumi paraméterek (neut-
rophil-lymphocyta arány - NLR, vérlemezke -lymphocyta arány - PLR, 
Fibrinogén és C-reaktív protein - CRP) prognosztikai jelentőségének elem-
zése.  
Módszerek: A Bécsi Tudományegyetemen TET miatt műtéten átesett, bár-
milyen stádiumú, illetve tíz európai és két kanadai centrumban pleurális ter-
jedést mutató TET miatt operált beteg standardizált adatbázisát elemeztük. A 
kísérletes részben tumor szöveteket és vérmintákat gyűjtöttünk betegektől, 
akiknél TET alakult ki, jóindulatú thymus betegségtől szenvedő páciensektől, 
valamint egészséges önkéntesektől.   
Eredmények: 
Patológiai prediktív faktorok: A teljes sebészi reszekció és a klinikai stá-
dium voltak a szignifikáns prognosztikai faktorok minden stádiumú TET 
estében. A pleurális érintettséget a vizsgált esetek 89%-ában thymomák, 
11.2%-ban thymus carcinoma (TC) okozta. A daganat eltávolítása érdekében 
negyven extrapleurális-pleuropulmonektómia (EPP), 23 teljes pleurektómia (TP) 
és 88 részleges pleurektómia (LP) történt (76.8%-ban teljes tumoreltávolítást el-
érve). A teljes túlélés (overall survival – OS) a teljes beteg populációt tekintve 1, 
3, 5 és 10 év után 96.4%, 91.0%, 87.2% és 62.7% volt. Nem volt szignifikáns 
különbség az OS és a kiújulás mentes túlélés (freedom from recurrence – FFR) 
tekintetében lokalizált és kiterjed daganatok esetén sem az EPP-n, TP-n vagy 




FFR-t és az betegségspecifikus túlélést (cause specific survival – CSS) is. A 
nem teljes sebészi eltávolítás szintén rosszabb OS-t jósolt.  
A túlélés kezelés előtti jelzői: A kezelés előtti szérum CRP és plazma fibri-
nogén koncentráció, valamint az NLR és PLR is szignifikánsan emelkedettebb 
volt TET jelenlétekor, különösképpen TC és késői tumorstádium esetén. A ke-
zelés előtt mért magas CRP, fibrinogén, NLR és PLR rosszabb túlélést jelentett.  
Az onkológiai követés biomarkerei:  
Azoknál a betegeknél, akiknél a daganat kiújult, magasabb szérum CRP kon-
centráció, NLR és PLR volt megfigyelhető. 
 
Következtetés: A széles körben elfogadott prognosztikai faktorok, mint a stá-
dium és reszekciós státusz ebben a betegcsoportban is igazolódtak. Továbbá, 
TET és plurális érintettség esetén továbbra is a sebészi eltávolítás marad a keze-
lés legfőbb lépése.  EPP-vel, TP-vel és LP-vel különböző tumor terjedések esetén 
alkalmazva, kiváló lokális kontrollt és túlélést lehet elérni. A perifériás vérből 
vehető gyulladásos markerek: a CRP, fibrinogén, NLR és PLR lehetséges prog-
nosztikai értékének vizsgálatához prospektív tanulmányra van szükség, mivel ez 
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